Trial Outcomes & Findings for Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma (NCT NCT03207243)

NCT ID: NCT03207243

Last Updated: 2020-03-02

Results Overview

Loss of asthma control is defined as: Asthma Control Questionnaire (ACQ-5) score increase from Baseline \>=0.5 point or pre-bronchodilator forced expiratory volume in 1 second (FEV1) decrease from baseline \>7.5 % or inability to titrate inhaled corticosteroid or a clinically significant asthma exacerbation (requiring oral corticosteroid \[OCS\] and/or hospitalization). The analysis shown is for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment. Baseline is defined as Day1. Percentage of participants experiencing loss of asthma control up to Week 16 has been presented. Modified Intent-to-Treat (Loss of Control) (mITT\_LoC) population consisted of all randomized participants who took at least 1 dose of study treatment and if participants experienced loss of asthma control, they were analyzed according to actual treatment at time of loss of control.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

165 participants

Primary outcome timeframe

Up to Week 16

Results posted on

2020-03-02

Participant Flow

This was a randomized, double-blind, placebo-controlled, parallel-group multicenter study to assess the efficacy, safety and tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of GSK3772847 in participants with moderately severe asthma.

A total of 165 participants with moderately severe asthma were randomized to receive GSK3772847 or placebo.

Participant milestones

Participant milestones
Measure	Placebo Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Overall Study STARTED	82	83
Overall Study COMPLETED	23	39
Overall Study NOT COMPLETED	59	44

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Overall Study Adverse Event	2	2
Overall Study Loss of Asthma Control	47	31
Overall Study Withdrawal by Subject	2	4
Overall Study Physician Decision	1	1
Overall Study Lost to Follow-up	0	1
Overall Study Protocol Specified Withdrawal Criteria	7	2
Overall Study Protocol Violation	0	3

Baseline Characteristics

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	Total n=165 Participants Total of all reporting groups
Age, Continuous	54.1 Years STANDARD_DEVIATION 11.65 • n=5 Participants	51.8 Years STANDARD_DEVIATION 11.74 • n=7 Participants	52.9 Years STANDARD_DEVIATION 11.71 • n=5 Participants
Sex: Female, Male Female	54 Participants n=5 Participants	64 Participants n=7 Participants	118 Participants n=5 Participants
Sex: Female, Male Male	28 Participants n=5 Participants	19 Participants n=7 Participants	47 Participants n=5 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	14 Participants n=5 Participants	8 Participants n=7 Participants	22 Participants n=5 Participants
Race/Ethnicity, Customized Central/South Asian Heritage	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race/Ethnicity, Customized Japanese /East Asian/South East Asian Heritage	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race/Ethnicity, Customized Black or African American	3 Participants n=5 Participants	8 Participants n=7 Participants	11 Participants n=5 Participants
Race/Ethnicity, Customized White	64 Participants n=5 Participants	66 Participants n=7 Participants	130 Participants n=5 Participants

PRIMARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) (mITT\_LoC) Population. Only those participants with data available at indicated time points were analyzed.

Outcome measures

Outcome measures
Measure	Placebo n=70 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=70 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With Loss of Asthma Control Over Weeks 0-16	81 Percentage of participants	67 Percentage of participants

SECONDARY outcome

Timeframe: Baseline and up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points who experienced loss of asthma control were analyzed.

The ACQ-5 is a five-item, self-completed questionnaire, which measures asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. ACQ-5 score ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicate lower asthma control. Baseline is the latest available assessment prior to first dose (Day 1). Change from Baseline was calculated by subtracting Baseline value from the specified time point value. A change of \>=0.5 in score suggests a clinically important change in score. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment

Outcome measures

Outcome measures
Measure	Placebo n=57 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=47 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With >=0.5 Point Asthma Control Questionnaire (ACQ-5) Score Increase From Baseline	39 Percentage of participants	30 Percentage of participants

SECONDARY outcome

Timeframe: Baseline and up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points who experienced loss of asthma control were analyzed.

Pulmonary function is measured by FEV1. FEV1 is the amount of air expired in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline is defined as the latest available pre-dose assessment (Day 1). Decrease from Baseline \>7.5 % in score suggests worsening of condition.

Outcome measures

Outcome measures
Measure	Placebo n=57 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=47 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants Who Have Pre-bronchodilator FEV1 Decrease From Baseline >7.5 %	63 Percentage of participants	68 Percentage of participants

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points who experienced loss of asthma control were analyzed.

Corticosteroid titration allows overall clinical evaluation of the participant's asthma status taking into account both lung function and symptom control. Inability to titrate inhaled corticosteroids indicates loss of asthma control.

Outcome measures

Outcome measures
Measure	Placebo n=57 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=47 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With Inability to Titrate Inhaled Corticosteroids (ICS)	23 Percentage of participants	30 Percentage of participants

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points who experienced loss of asthma control were analyzed.

A clinically significant asthma exacerbation is defined as one requiring oral corticosteroid and/or hospitalization.

Outcome measures

Outcome measures
Measure	Placebo n=57 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=47 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With Clinically Significant Asthma Exacerbation	7 Percentage of participants	13 Percentage of participants

SECONDARY outcome

Timeframe: Up to Week 6

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points were analyzed.

Loss of asthma control is defined as: ACQ-5 score increase from Baseline \>=0.5 point or pre-bronchodilator FEV1 decrease from Baseline \>7.5 % or inability to titrate inhaled corticosteroid or a clinically significant asthma exacerbation (requiring oral OCS and/or hospitalization). The analysis shown is for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment. Baseline is defined as Day1. Percentage of participants experiencing loss of asthma control up to Week 6 has been presented.

Outcome measures

Outcome measures
Measure	Placebo n=70 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=72 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With Loss of Asthma Control Over Weeks 0-6	50 Percentage of participants	36 Percentage of participants

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points who experienced loss of asthma control were analyzed.

Time to loss of asthma control was analyzed using Kaplan-Meier analysis. In this analysis, participants were either be counted as an event or they were censored. An event is defined as participants who experience loss of asthma control during the study. Censoring is defined as participants who discontinued investigational product for reasons other than loss of asthma control. The analysis shown is for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment. Participants who didn't experience loss of asthma control were also censored at day 113.

Outcome measures

Outcome measures
Measure	Placebo n=57 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=47 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Time to Loss of Asthma Control	50 Days Interval 29.0 to NA indicates data could not be calculated due to insufficient number of participants with events.	96 Days Interval 31.0 to NA indicates data could not be calculated due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat (Loss of Control) Population. Only those participants with data available at indicated time points who experienced loss of asthma control were analyzed.

A clinically significant asthma exacerbation is defined as one requiring oral corticosteroid and/or hospitalization. Participants with clinically significant asthma exacerbation or inability to titrate FP indicated loss of asthma control.

Outcome measures

Outcome measures
Measure	Placebo n=57 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=47 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With Clinically Significant Asthma Exacerbation or Inability to Titrate	25 Percentage of participants	40 Percentage of participants

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat (mITT) population consisted of all randomized participants who took at least 1 dose of study treatment and were analyzed according to the treatment they received \>=50% of the time.

Hospitalization is defined as an inpatient stay or least an overnight stay at the hospital or emergency ward for observation or other equivalent facility. Data has been presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=78 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Number of Participants Experiencing Asthma Related Hospitalization During the Study Period	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat Population.

An event is defined as an on-treatment asthma-related hospitalization or emergency room visit and participants can contribute to more than one event. Rate is calculated as number of events \* 1000 divided by (number of participants in treatment group \* mean treatment exposure in years). Data has been presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=78 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Rate Per 1000 Person-years of Participants With Hospitalization	70.5 Events per person-year	0 Events per person-year

SECONDARY outcome

Timeframe: Up to Week 16

Population: Modified Intent-to-Treat Population.

The number of hospitalization or emergency room visit made by per participant due to loss of asthma control have been presented in category titles. Data has been presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=78 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Number of Hospitalizations or Emergency Room Visits Per Participants 0	77 Participants	78 Participants
Number of Hospitalizations or Emergency Room Visits Per Participants 1	1 Participants	0 Participants
Number of Hospitalizations or Emergency Room Visits Per Participants 2	0 Participants	0 Participants
Number of Hospitalizations or Emergency Room Visits Per Participants >=3	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and Week 16

Population: Modified Intent-to-Treat Population. Only those participants with data available at indicated time points were analyzed. Participants with data available at specified time points were represented by n=x in the category titles.

ACQ-5 is a five-item, self-completed questionnaire, which measures asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath \& wheeze) enquire about the frequency \&/or severity of symptoms over the previous week. The response options range from zero (no impairment/limitation) to six (total impairment/limitation) scale. ACQ-5 score ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicate lower asthma control. Baseline is the latest available assessment prior to first dose (Day 1). Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=72 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=73 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week9; n=30, 42	-0.93 Scores on a scale Standard Deviation 0.713	-0.97 Scores on a scale Standard Deviation 0.817
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week1; n=72, 73	-0.36 Scores on a scale Standard Deviation 0.713	-0.48 Scores on a scale Standard Deviation 0.685
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week2; n=67, 68	-0.53 Scores on a scale Standard Deviation 0.666	-0.74 Scores on a scale Standard Deviation 0.732
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week3; n=61, 61	-0.59 Scores on a scale Standard Deviation 0.722	-0.78 Scores on a scale Standard Deviation 0.663
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week4; n=54, 59	-0.69 Scores on a scale Standard Deviation 0.733	-0.79 Scores on a scale Standard Deviation 0.695
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week5; n= 42, 52	-0.80 Scores on a scale Standard Deviation 0.839	-0.78 Scores on a scale Standard Deviation 0.804
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week6; n=40, 48	-0.80 Scores on a scale Standard Deviation 0.907	-0.93 Scores on a scale Standard Deviation 0.692
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week7; n=34, 46	-0.92 Scores on a scale Standard Deviation 0.710	-0.93 Scores on a scale Standard Deviation 0.785
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week8; n=33, 44	-0.95 Scores on a scale Standard Deviation 0.769	-1.00 Scores on a scale Standard Deviation 0.755
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week10; n=29, 41	-0.97 Scores on a scale Standard Deviation 0.820	-0.99 Scores on a scale Standard Deviation 0.729
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week11; n=22, 38	-1.05 Scores on a scale Standard Deviation 0.907	-1.07 Scores on a scale Standard Deviation 0.770
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week12; n=23, 38	-0.88 Scores on a scale Standard Deviation 1.134	-1.16 Scores on a scale Standard Deviation 0.795
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week13; n=17,32	-1.40 Scores on a scale Standard Deviation 0.860	-1.06 Scores on a scale Standard Deviation 0.773
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week14; n=17, 31	-1.33 Scores on a scale Standard Deviation 0.943	-1.14 Scores on a scale Standard Deviation 0.820
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week15; n=17, 27	-1.22 Scores on a scale Standard Deviation 0.874	-1.21 Scores on a scale Standard Deviation 0.814
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score Week16; n=12, 21	-1.15 Scores on a scale Standard Deviation 1.102	-1.17 Scores on a scale Standard Deviation 0.738

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and Week 16

ACQ-5 is a five-item, self-completed questionnaire, which measures asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath \& wheeze) enquire about the frequency \&/or severity of symptoms over the previous week. The response options range from zero (no impairment/limitation) to six (total impairment/limitation) scale. ACQ-5 score ranges from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicate lower asthma control. Baseline is the latest available assessment prior to first dose (Day 1). Change from Baseline was calculated by subtracting Baseline value from the specified time point value. A responder is defined as participants with change from Baseline of \<= -0.5 point at given time point. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=72 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=73 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week1; n=72, 73	38 Percentage of participants	41 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week2; n=67, 68	46 Percentage of participants	56 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week3; n=61, 61	49 Percentage of participants	56 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week4; n=54, 59	59 Percentage of participants	61 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week5; n= 42, 52	62 Percentage of participants	65 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week6; n=40, 48	63 Percentage of participants	69 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week7; n=34, 46	74 Percentage of participants	65 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week8; n=33, 44	70 Percentage of participants	73 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week9; n=30, 42	70 Percentage of participants	71 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week10; n=29, 41	69 Percentage of participants	76 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week11; n=22, 38	64 Percentage of participants	79 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week12; n=23, 38	57 Percentage of participants	79 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week13; n=17,32	82 Percentage of participants	75 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week14; n=17, 31	71 Percentage of participants	74 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week15; n=17, 27	76 Percentage of participants	74 Percentage of participants
Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder) Week16; n=12, 21	67 Percentage of participants	81 Percentage of participants

SECONDARY outcome

Timeframe: Baseline and Weeks 4, 8, 12 and 16

SGRQ is a disease-specific questionnaire designed to measure impact of respiratory disease and its treatment on Health-related quality of life (HRQoL) of participants with Chronic Obstructive Pulmonary Disease (COPD). It contains 14 questions with a total of 40 items grouped into domains (Symptoms, Activity and Impacts). SGRQ total score was calculated as 100 multiplied by summed weights from all positive items divided by sum of weights for all items in questionnaire. It ranges from 0 to 100, higher score indicates poor HRQoL. Baseline is defined as the latest available assessment prior to first dose (Day 1). Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=43 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=52 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score Week4; n=43, 52	-10.0 Scores on a scale Standard Deviation 14.98	-7.0 Scores on a scale Standard Deviation 11.41
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score Week8; n=31, 42	-10.7 Scores on a scale Standard Deviation 15.32	-7.2 Scores on a scale Standard Deviation 17.08
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score Week12; n=23, 35	-15.8 Scores on a scale Standard Deviation 21.42	-12.9 Scores on a scale Standard Deviation 14.91
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score Week16; n=16, 26	-12.4 Scores on a scale Standard Deviation 20.75	-16.5 Scores on a scale Standard Deviation 18.51

SECONDARY outcome

Timeframe: Baseline and Weeks 4, 8, 12 and 16

Population: Modified Intent-to-Treat Population. Only those participants with data available at the indicated time points were analyzed. Participants with data available at specified time points were represented by n=x in the category titles.

SGRQ is a disease-specific questionnaire designed to measure impact of respiratory disease and its treatment on HRQoL of participants with COPD. It contains 14 questions with a total of 40 items grouped into domains (Symptoms, Activity and Impacts). SGRQ total score was calculated as 100 multiplied by summed weights from all positive items divided by sum of weights for all items in questionnaire. It ranges from 0 to 100, higher score indicates poor HRQoL. Baseline is defined as the latest available assessment prior to first dose (Day 1). A responder is defined as a change from Baseline of \<= -4 at the given time point. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=43 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=52 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percentage of Participants With at Least a 4 Units Improvement From Baseline of St. George's Respiratory Questionnaire (SGRQ) Week4; n=43, 52	60 Percentage of participants	58 Percentage of participants
Percentage of Participants With at Least a 4 Units Improvement From Baseline of St. George's Respiratory Questionnaire (SGRQ) Week8; n=31, 42	61 Percentage of participants	67 Percentage of participants
Percentage of Participants With at Least a 4 Units Improvement From Baseline of St. George's Respiratory Questionnaire (SGRQ) Week12; n=23, 35	70 Percentage of participants	74 Percentage of participants
Percentage of Participants With at Least a 4 Units Improvement From Baseline of St. George's Respiratory Questionnaire (SGRQ) Week16; n=16, 26	69 Percentage of participants	88 Percentage of participants

SECONDARY outcome

Timeframe: Baseline and Weeks 2, 4, 6, 8, 10, 12, 14 and 16

Pre-bronchodilator FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is defined as the latest available assessment prior to first dose (Day 1) and change from Baseline was calculated by subtracting Baseline value from the specified time point value. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=64 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=66 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week2; n=64, 66	0.094 Liters Standard Deviation 0.2359	0.089 Liters Standard Deviation 0.2443
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week4; n=48, 56	0.074 Liters Standard Deviation 0.3077	0.086 Liters Standard Deviation 0.2325
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week6; n=38, 50	0.078 Liters Standard Deviation 0.2610	0.135 Liters Standard Deviation 0.3758
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week8; n=33, 45	0.049 Liters Standard Deviation 0.2888	0.089 Liters Standard Deviation 0.2236
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week10; n=33, 43	0.047 Liters Standard Deviation 0.2563	0.066 Liters Standard Deviation 0.2372
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week12; n=23, 36	0.061 Liters Standard Deviation 0.2759	0.037 Liters Standard Deviation 0.2637
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week14; n=21, 36	0.079 Liters Standard Deviation 0.2824	0.047 Liters Standard Deviation 0.3200
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Week16; n=15, 26	0.063 Liters Standard Deviation 0.3383	0.025 Liters Standard Deviation 0.3008

SECONDARY outcome

Timeframe: Baseline and Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16.

PEF is maximum speed of expiration measured, using spirometer. The device was distributed to participants at Visit 1, to measure PEF twice-daily (morning upon waking \& in the evening just before going to bed). Participants were encouraged to perform morning \& evening PEF measurements before the use of any long-acting beta-agonists (LABAs) or rescue medication. Highest of 3 values were recorded in eDairy.Baseline was calculated over the last 7 days of run-in period prior to Visit 2 (Week 0). Participants with at least 4 full days of data in the last 7 days of run-in were included. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Mean PEF was calculated for each participant during the four weekly periods (Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16).Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment

Outcome measures

Outcome measures
Measure	Placebo n=76 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=77 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Morning PEF: Weeks 1-4,n=76, 76	4.13 Liters/minute Standard Deviation 35.492	4.32 Liters/minute Standard Deviation 43.773
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Morning PEF: Weeks 5-8,n=50, 56	-1.84 Liters/minute Standard Deviation 65.222	-3.82 Liters/minute Standard Deviation 46.621
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Morning PEF: Weeks 9-12,n=31, 43	-4.15 Liters/minute Standard Deviation 46.588	-1.69 Liters/minute Standard Deviation 45.192
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Morning PEF: Weeks 13-16,n=20, 38	-7.88 Liters/minute Standard Deviation 47.190	-1.83 Liters/minute Standard Deviation 69.866
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Evening PEF: Weeks 1-4,n=76, 77	0.43 Liters/minute Standard Deviation 36.087	2.45 Liters/minute Standard Deviation 37.712
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Evening PEF: Weeks 5-8,n=52, 58	-6.96 Liters/minute Standard Deviation 61.987	-4.38 Liters/minute Standard Deviation 49.076
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Evening PEF: Weeks 9-12,n=33, 44	-0.77 Liters/minute Standard Deviation 54.768	-0.58 Liters/minute Standard Deviation 39.929
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF Evening PEF: Weeks 13-16,n=21, 38	-10.81 Liters/minute Standard Deviation 51.566	-1.16 Liters/minute Standard Deviation 63.383

SECONDARY outcome

Timeframe: Baseline and Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16

Asthma symptoms experienced by participants during the day was recorded in e-Diary every evening before going to bed in form of scores on a 5-point rating scale. Scores ranged from 0=no daytime asthma symptoms to 4=very severe daytime asthma symptoms. Baseline was calculated over the last 7 days of run-in period prior to Visit 2 (Week 0). Participants with at least 4 full days of data in the last 7 days of run-in were included. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. The mean asthma symptom score was calculated for each participant during the four weekly periods (Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16). Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=78 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Mean Daytime Asthma Symptom Score Over Each Four Weeks of the 16 Week Treatment Period Weeks 1-4, n=77, 78	-0.09 Scores on a scale Standard Deviation 0.472	-0.02 Scores on a scale Standard Deviation 0.337
Change From Baseline in Mean Daytime Asthma Symptom Score Over Each Four Weeks of the 16 Week Treatment Period Weeks 5-8, n=52, 59	-0.18 Scores on a scale Standard Deviation 0.610	-0.09 Scores on a scale Standard Deviation 0.460
Change From Baseline in Mean Daytime Asthma Symptom Score Over Each Four Weeks of the 16 Week Treatment Period Weeks 9-12 ,n=33,34	-0.29 Scores on a scale Standard Deviation 0.631	-0.08 Scores on a scale Standard Deviation 0.473
Change From Baseline in Mean Daytime Asthma Symptom Score Over Each Four Weeks of the 16 Week Treatment Period Weeks 13-16, n=21, 38	-0.29 Scores on a scale Standard Deviation 0.692	-0.17 Scores on a scale Standard Deviation 0.458

SECONDARY outcome

Timeframe: Baseline and Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16

The mean number of inhalation of rescue medication (albuterol/salbutamol) used to relieve symptoms immediately during the day and night was recorded in eDiary from Baseline until Week 16. Baseline was calculated over the last 7 days of run-in period prior to Visit 2 (Week 0). Participants with at least 4 full days of data in the last 7 days of run-in were included. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. The mean rescue medication use was calculated for each participant during the four weekly periods (Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16). Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=75 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Mean Daily Rescue Medication Use (Albuterol/Salbutamol) Weeks 1-4, n=78, 75	-0.52 Inhalations per day Standard Deviation 2.554	-1.09 Inhalations per day Standard Deviation 4.687
Change From Baseline in Mean Daily Rescue Medication Use (Albuterol/Salbutamol) Weeks 5-8, n=56, 57	-0.52 Inhalations per day Standard Deviation 1.740	-1.24 Inhalations per day Standard Deviation 5.180
Change From Baseline in Mean Daily Rescue Medication Use (Albuterol/Salbutamol) Weeks 9-12, n=32, 42	-0.17 Inhalations per day Standard Deviation 0.945	-1.59 Inhalations per day Standard Deviation 5.934
Change From Baseline in Mean Daily Rescue Medication Use (Albuterol/Salbutamol) Weeks 13-16, n=24, 37	0.01 Inhalations per day Standard Deviation 2.005	-1.90 Inhalations per day Standard Deviation 6.624

SECONDARY outcome

Timeframe: Baseline and Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16

Participant captured night-time awakenings (yes/no) and use of rescue medication during these awakenings (yes/no) was recorded in e-Diary each morning. Percentage of night-time awakenings is calculated by number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data available\*100. Baseline was calculated over the last 7 days of run-in period prior to Visit 2 (Week 0). Participants having at least 4 full days of data in the last 7 days of run-in were included. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Night-time awakenings due to asthma symptoms requiring rescue medication was calculated for each participant during the four weekly periods (Weeks 1-4; Weeks 5-8, Weeks 9-12 and Weeks 13-16). Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=77 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=76 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Percent Night-time Awakenings Due to Asthma Symptoms Requiring Rescue Medication Use Weeks 1-4, n=77, 76	-3.80 Percentage of nights with awakenings Standard Deviation 25.712	-7.42 Percentage of nights with awakenings Standard Deviation 23.847
Change From Baseline in Percent Night-time Awakenings Due to Asthma Symptoms Requiring Rescue Medication Use Weeks 5-8,n=50, 56	-7.85 Percentage of nights with awakenings Standard Deviation 26.325	-10.49 Percentage of nights with awakenings Standard Deviation 31.081
Change From Baseline in Percent Night-time Awakenings Due to Asthma Symptoms Requiring Rescue Medication Use Weeks 9-12,n=31, 43	-5.67 Percentage of nights with awakenings Standard Deviation 24.669	-13.43 Percentage of nights with awakenings Standard Deviation 26.962
Change From Baseline in Percent Night-time Awakenings Due to Asthma Symptoms Requiring Rescue Medication Use Weeks 13-16,n=20, 38	-2.31 Percentage of nights with awakenings Standard Deviation 30.355	-14.91 Percentage of nights with awakenings Standard Deviation 33.544

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14 and 16

FeNO was assessed as a measure of airway inflammation using a handheld electronic device. The measurements recorded were according to standardized procedures by the American Thoracic Society and the European Respiratory Society Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide. FeNO measurements were obtained prior to FEV1 assessments. Participants did not use their rescue medication for at least 6 hours before each FeNO assessment, unless essential for clinical need. Baseline is defined as the latest available assessment prior to first dose (Day 1). Percent change from Baseline is calculated as ratio to Baseline minus one and multiplied by 100. Data is presented for primary estimand which includes all data collected, except for data collected after the date of loss of asthma control or early withdrawal from study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=60 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=63 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week14; n=19, 30	28.1 Percent Change Interval -43.0 to 483.0	1.7 Percent Change Interval -48.0 to 457.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week1; n=60, 63	-3.6 Percent Change Interval -46.0 to 126.0	-4.9 Percent Change Interval -57.0 to 281.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week2; n=58, 59	15.4 Percent Change Interval -57.0 to 481.0	0.0 Percent Change Interval -66.0 to 206.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week4; n=41, 50	15.2 Percent Change Interval -64.0 to 302.0	3.3 Percent Change Interval -69.0 to 546.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week6; n=34, 46	5.0 Percent Change Interval -71.0 to 537.0	0.0 Percent Change Interval -62.0 to 221.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week8; n=29, 38	15.9 Percent Change Interval -60.0 to 548.0	-2.9 Percent Change Interval -40.0 to 148.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week10; n=29, 37	13.8 Percent Change Interval -54.0 to 483.0	0.0 Percent Change Interval -52.0 to 252.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week12; n=19, 31	31.4 Percent Change Interval -40.0 to 422.0	8.8 Percent Change Interval -47.0 to 413.0
Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Week16; n=13, 22	85.9 Percent Change Interval -33.0 to 635.0	12.7 Percent Change Interval -51.0 to 695.0

SECONDARY outcome

Timeframe: Up to Week 16

Population: Safety Population consists of all randomized participants who took at least 1 dose of study treatment.

A non-SAE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment were categorized as SAE.

Outcome measures

Outcome measures
Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Number of Participants Reporting Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs) non-SAE	20 Participants	19 Participants
Number of Participants Reporting Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs) SAE	1 Participants	2 Participants

SECONDARY outcome

Timeframe: Baseline and Week 0 (Post-dose), Week1, Week 2, Week 4 (Pre and Post dose), Week 6, Week 8 (Pre and Post dose), Week 10, Week 12 (Pre and Post dose), Week 14, Week 16, Week 20, Week 24 and Week 28

Population: Safety Population. Participants with data available at specified time points were represented by n=x in the category titles.

DBP and SBP were measured in semi-supine position after 5 minutes rest. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Data for change from Baseline for post dose values have been presented.

Outcome measures

SECONDARY outcome

Population: Safety Population. Participants with data available at specified time points were represented by n=x in the category titles.

Pulse rate was measured in semi-supine position after 5 minutes rest. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value. Data for change from Baseline for post dose values have been presented.

Outcome measures

Outcome measures
Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Pulse Rate (PR) Post-dose: Week0; n=82, 83	-2.2 Beats per minute Standard Deviation 7.20	-0.1 Beats per minute Standard Deviation 6.54
Change From Baseline in Pulse Rate (PR) Week1; n=79, 75	0.8 Beats per minute Standard Deviation 6.12	3.1 Beats per minute Standard Deviation 7.95
Change From Baseline in Pulse Rate (PR) Week2; n=73, 75	2.9 Beats per minute Standard Deviation 7.31	1.7 Beats per minute Standard Deviation 7.86
Change From Baseline in Pulse Rate (PR) Pre-dose:Week4; n=49, 59	-0.3 Beats per minute Standard Deviation 9.73	0.1 Beats per minute Standard Deviation 9.72
Change From Baseline in Pulse Rate (PR) Post-dose:Week4; n=48, 59	-2.0 Beats per minute Standard Deviation 10.00	-1.0 Beats per minute Standard Deviation 10.93
Change From Baseline in Pulse Rate (PR) Week6; n=45, 57	3.3 Beats per minute Standard Deviation 11.85	2.8 Beats per minute Standard Deviation 9.26
Change From Baseline in Pulse Rate (PR) Pre-dose: Week8; n=34, 47	-0.3 Beats per minute Standard Deviation 9.11	1.0 Beats per minute Standard Deviation 7.62
Change From Baseline in Pulse Rate (PR) Post-dose: Week8; n=34, 47	-0.9 Beats per minute Standard Deviation 10.39	-0.6 Beats per minute Standard Deviation 9.71
Change From Baseline in Pulse Rate (PR) Week10; n=34, 46	2.6 Beats per minute Standard Deviation 8.86	2.4 Beats per minute Standard Deviation 6.72
Change From Baseline in Pulse Rate (PR) Pre-dose: Week12; n=24, 39	2.8 Beats per minute Standard Deviation 8.04	1.7 Beats per minute Standard Deviation 7.53
Change From Baseline in Pulse Rate (PR) Post-dose: Week12; n=24, 39	0.9 Beats per minute Standard Deviation 8.84	-1.2 Beats per minute Standard Deviation 10.57
Change From Baseline in Pulse Rate (PR) Week14; n=24, 39	3.1 Beats per minute Standard Deviation 9.81	3.6 Beats per minute Standard Deviation 6.62
Change From Baseline in Pulse Rate (PR) Week16; n=24, 39	3.5 Beats per minute Standard Deviation 9.14	2.6 Beats per minute Standard Deviation 8.30
Change From Baseline in Pulse Rate (PR) Week20; n=76, 78	2.1 Beats per minute Standard Deviation 8.34	3.6 Beats per minute Standard Deviation 9.48
Change From Baseline in Pulse Rate (PR) Week24; n=75, 76	2.3 Beats per minute Standard Deviation 8.00	2.5 Beats per minute Standard Deviation 7.98
Change From Baseline in Pulse Rate (PR) Week28; n=74, 77	2.5 Beats per minute Standard Deviation 8.50	2.3 Beats per minute Standard Deviation 7.98

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4, 8 and 12

Population: Safety Population. Participants with data available at specified time points were represented by n=x in the category titles.

DBP and SBP was measured pre-dose and post-dose in semi-supine position after 5 minutes rest. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP SBP: Week0; n=82, 83	-2.0 mmHg Standard Deviation 8.05	1.3 mmHg Standard Deviation 7.19
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP SBP: Week4; n=48, 59	-0.4 mmHg Standard Deviation 5.70	2.4 mmHg Standard Deviation 9.32
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP SBP: Week8; n=34, 47	-0.8 mmHg Standard Deviation 6.03	1.9 mmHg Standard Deviation 6.58
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP SBP: Week12; n=24, 39	-0.9 mmHg Standard Deviation 7.51	1.8 mmHg Standard Deviation 8.72
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP DBP: Week0; n=82, 83	-0.7 mmHg Standard Deviation 6.58	-0.3 mmHg Standard Deviation 5.67
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP DBP: Week4; n=48, 59	0.4 mmHg Standard Deviation 4.95	-0.1 mmHg Standard Deviation 6.76
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP DBP: Week8; n=34, 47	0.2 mmHg Standard Deviation 4.38	0.8 mmHg Standard Deviation 5.55
Change From Baseline Between Post-dose and Pre-dose in DBP and SBP DBP: Week12; n=24, 39	-0.3 mmHg Standard Deviation 4.70	-1.1 mmHg Standard Deviation 6.08

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4, 8 and 12

Population: Safety Population. Participants with data available at specified time points were represented by n=x in the category titles.

Pulse rate was measured pre-dose and post-dose in semi-supine position after 5 minutes rest. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline Between Post-dose and Pre-dose in Pulse Rate Week0; n=82, 83	-2.2 Beats per minute Standard Deviation 7.20	-0.1 Beats per minute Standard Deviation 6.54
Change From Baseline Between Post-dose and Pre-dose in Pulse Rate Week4; n=48, 59	-1.6 Beats per minute Standard Deviation 5.75	-1.1 Beats per minute Standard Deviation 6.85
Change From Baseline Between Post-dose and Pre-dose in Pulse Rate Week8; n=34, 47	-0.5 Beats per minute Standard Deviation 7.21	-1.6 Beats per minute Standard Deviation 6.02
Change From Baseline Between Post-dose and Pre-dose in Pulse Rate Week12; n=24, 39	-2.0 Beats per minute Standard Deviation 5.97	-2.9 Beats per minute Standard Deviation 9.05

SECONDARY outcome

Timeframe: Baseline and Week 0 (Post-dose), Week 4 (Pre and Post dose), Week 8 (Pre and Post dose), Week 12 (Pre and Post dose) and Week 16

Population: Safety Population. Only those participants with data available at indicated time points were analyzed. Participants with data available at specified time points were represented by n=x in the category titles.

Triplicate 12-lead ECGs were recorded pre-dose and post-dose with participant in semi-supine position after 5 minutes rest. At each time point ECG was taken using an ECG machine that automatically measures PR interval, QRS duration, uncorrected QT interval, QTcF interval and RR interval. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=80 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Pre-dose: Week4; n=49, 59	-1.7 milliseconds Standard Deviation 21.48	-1.8 milliseconds Standard Deviation 17.93
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Pre-dose: Week8; n=34, 47	3.5 milliseconds Standard Deviation 23.67	-4.7 milliseconds Standard Deviation 20.53
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT Pre-dose:Week12; n=24, 39	1.5 milliseconds Standard Deviation 22.31	-3.1 milliseconds Standard Deviation 23.54
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Week16; n=24,39	-2.2 milliseconds Standard Deviation 21.15	-7.3 milliseconds Standard Deviation 20.68
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Pre-dose:Week8; n=34, 47	6.4 milliseconds Standard Deviation 13.00	-0.9 milliseconds Standard Deviation 14.54
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Post-dose:Week8; n=33, 47	5.5 milliseconds Standard Deviation 12.86	5.8 milliseconds Standard Deviation 16.08
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Pre-dose:Week12; n=24, 39	3.3 milliseconds Standard Deviation 13.45	0.4 milliseconds Standard Deviation 17.56
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF: Week16; n=24, 39	-0.5 milliseconds Standard Deviation 11.87	-2.2 milliseconds Standard Deviation 14.83
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Pre-dose:Week8; n=34, 47	-17.4 milliseconds Standard Deviation 135.17	-24.2 milliseconds Standard Deviation 92.65
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Post-dose:Week8; n=33, 47	10.8 milliseconds Standard Deviation 176.36	10.7 milliseconds Standard Deviation 97.02
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Pre-dose:Week12; n=24, 39	-12.6 milliseconds Standard Deviation 107.36	-21.6 milliseconds Standard Deviation 100.97
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Post-dose:Week12; n=24, 39	-4.8 milliseconds Standard Deviation 148.89	1.3 milliseconds Standard Deviation 118.83
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Week16; n=24, 39	-14.4 milliseconds Standard Deviation 113.07	-33.9 milliseconds Standard Deviation 102.02
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Pre-dose: Week8; n=34, 47	0.0 milliseconds Standard Deviation 8.69	1.4 milliseconds Standard Deviation 11.70
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Post-dose: Week0; n=80, 80	1.8 milliseconds Standard Deviation 9.77	3.1 milliseconds Standard Deviation 9.28
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Pre-dose: Week4; n=49, 59	-0.4 milliseconds Standard Deviation 7.91	1.3 milliseconds Standard Deviation 10.93
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Post-dose: Week4; n=48, 59	1.2 milliseconds Standard Deviation 9.74	1.9 milliseconds Standard Deviation 11.76
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR:Post-dose: Week8; n=33, 47	0.5 milliseconds Standard Deviation 11.47	1.5 milliseconds Standard Deviation 11.30
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Pre-dose:Week12; n=24, 39	-1.3 milliseconds Standard Deviation 9.51	-0.5 milliseconds Standard Deviation 13.17
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Post-dose Week12; n=24, 39	1.3 milliseconds Standard Deviation 10.85	2.2 milliseconds Standard Deviation 12.59
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval PR: Week16; n=24, 39	-0.6 milliseconds Standard Deviation 10.22	-0.7 milliseconds Standard Deviation 12.91
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Post-dose Week0; n=80, 80	0.0 milliseconds Standard Deviation 5.75	0.2 milliseconds Standard Deviation 5.60
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Pre-dose Week4; n=49, 59	-0.5 milliseconds Standard Deviation 5.69	0.7 milliseconds Standard Deviation 5.72
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS: Post-dose:Week4; n=48, 59	-0.2 milliseconds Standard Deviation 6.10	0.1 milliseconds Standard Deviation 6.14
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Pre-dose:Week8; n=34, 47	0.2 milliseconds Standard Deviation 5.86	-0.1 milliseconds Standard Deviation 4.90
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Post-dose:Week8; n=33, 47	0.5 milliseconds Standard Deviation 7.02	0.1 milliseconds Standard Deviation 4.87
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Pre-dose: Week12; n=24, 39	-1.3 milliseconds Standard Deviation 4.83	-1.1 milliseconds Standard Deviation 7.13
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Post-dose: Week12; n=24, 39	-0.7 milliseconds Standard Deviation 6.03	-1.8 milliseconds Standard Deviation 6.21
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QRS:Week16; n=24, 39	-1.6 milliseconds Standard Deviation 6.19	-2.0 milliseconds Standard Deviation 6.25
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Post-dose: Week0; n=80, 80	7.4 milliseconds Standard Deviation 19.67	3.5 milliseconds Standard Deviation 16.69
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Post-dose: Week4; n=48, 59	8.9 milliseconds Standard Deviation 23.09	5.1 milliseconds Standard Deviation 18.78
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Pre-dose: Week8; n=33, 47	6.7 milliseconds Standard Deviation 30.69	7.0 milliseconds Standard Deviation 23.49
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QT:Post-dose:Week12; n=24, 39	3.3 milliseconds Standard Deviation 24.38	2.4 milliseconds Standard Deviation 23.16
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Post-dose:Week0; n=80, 80	4.2 milliseconds Standard Deviation 12.56	3.8 milliseconds Standard Deviation 11.21
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Pre-dose:Week4; n=49, 59	-1.4 milliseconds Standard Deviation 11.35	-1.0 milliseconds Standard Deviation 12.10
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Post-dose:Week4; n=48, 59	4.0 milliseconds Standard Deviation 13.57	2.0 milliseconds Standard Deviation 12.46
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval QTcF:Post-dose: Week12; n=24, 39	4.4 milliseconds Standard Deviation 13.91	2.9 milliseconds Standard Deviation 14.33
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Post-dose: Week0; n=80, 80	24.0 milliseconds Standard Deviation 104.42	-0.2 milliseconds Standard Deviation 89.38
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Pre-dose: Week4; n=49, 59	-1.3 milliseconds Standard Deviation 114.81	-2.0 milliseconds Standard Deviation 96.20
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval RR:Post-dose: Week4; n=48, 59	36.2 milliseconds Standard Deviation 118.51	26.7 milliseconds Standard Deviation 110.84

SECONDARY outcome

Timeframe: Baseline and Week 0 (Post-dose), Week 4 (Pre and Post dose), Week 8 (Pre and Post dose), Week 12 (Pre and Post dose) and Week 16

Population: Safety Population. Participants with data available at specified time points were represented by n=x in the category titles.

Triplicate 12-lead ECGs were recorded pre-dose and post-dose with participant in semi-supine position after 5 minutes rest. At each time point ECG was taken using an ECG machine that automatically measures heart rate. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in ECG Heart Rate Post-dose: Week0; n=82, 83	-1.6 Beats per minute Standard Deviation 7.57	0.2 Beats per minute Standard Deviation 6.93
Change From Baseline in ECG Heart Rate Pre-dose: Week4; n=49, 59	0.4 Beats per minute Standard Deviation 9.06	0.7 Beats per minute Standard Deviation 7.94
Change From Baseline in ECG Heart Rate Post-dose: Week4; n=48, 59	-2.4 Beats per minute Standard Deviation 9.09	-1.0 Beats per minute Standard Deviation 8.48
Change From Baseline in ECG Heart Rate Pre-dose: Week8; n=34, 47	1.5 Beats per minute Standard Deviation 11.81	1.9 Beats per minute Standard Deviation 6.98
Change From Baseline in ECG Heart Rate Post-dose: Week8; n=33, 47	-0.3 Beats per minute Standard Deviation 15.59	-0.4 Beats per minute Standard Deviation 7.57
Change From Baseline in ECG Heart Rate Pre-dose:Week12; n=24, 39	0.6 Beats per minute Standard Deviation 8.98	1.6 Beats per minute Standard Deviation 7.56
Change From Baseline in ECG Heart Rate Post-dose Week12; n=24, 39	0.4 Beats per minute Standard Deviation 12.44	0.5 Beats per minute Standard Deviation 9.28
Change From Baseline in ECG Heart Rate Week16; n=24, 39	0.5 Beats per minute Standard Deviation 10.04	3.1 Beats per minute Standard Deviation 8.12

SECONDARY outcome

Timeframe: Baseline and Week 4 (Pre and Post dose), Week 8 (Pre and Post dose), Week 12 (Pre and Post dose) and Week 16

Triplicate 12-lead ECGs were recorded with participant in semi-supine position after 5 minutes rest. At each time point ECG was taken using an ECG machine that automatically measures QRS axis. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=80 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in QRS Axis Post-dose: Week0; n=80, 80	-0.8 Degrees Standard Deviation 10.76	1.9 Degrees Standard Deviation 6.75
Change From Baseline in QRS Axis Pre-dose: Week4; n=49, 59	0.7 Degrees Standard Deviation 14.30	2.3 Degrees Standard Deviation 13.77
Change From Baseline in QRS Axis Post-dose: Week4; n=48, 59	-0.1 Degrees Standard Deviation 16.72	1.4 Degrees Standard Deviation 11.95
Change From Baseline in QRS Axis Pre-dose: Week8; n=34, 47	-0.2 Degrees Standard Deviation 10.56	-1.0 Degrees Standard Deviation 9.34
Change From Baseline in QRS Axis Post-dose: Week8; n=33, 47	1.0 Degrees Standard Deviation 9.88	-1.2 Degrees Standard Deviation 8.37
Change From Baseline in QRS Axis Pre-dose:Week12; n=24, 39	0.2 Degrees Standard Deviation 8.59	2.0 Degrees Standard Deviation 31.39
Change From Baseline in QRS Axis Post-dose Week12; n=24, 39	-1.3 Degrees Standard Deviation 9.49	-1.2 Degrees Standard Deviation 15.73
Change From Baseline in QRS Axis Week16; n=24, 39	2.3 Degrees Standard Deviation 11.35	-1.4 Degrees Standard Deviation 10.88

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4, 8 and 12

Outcome measures

Outcome measures
Measure	Placebo n=80 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QRS:Week12; n=24, 39	0.7 milliseconds Standard Deviation 5.36	-0.9 milliseconds Standard Deviation 4.60
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval PR:Week0; n=80, 80	1.8 milliseconds Standard Deviation 9.77	3.1 milliseconds Standard Deviation 9.28
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval PR: Week4; n=48, 59	1.7 milliseconds Standard Deviation 8.04	0.5 milliseconds Standard Deviation 9.77
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval PR: Week8; n=33, 47	0.3 milliseconds Standard Deviation 8.70	-0.1 milliseconds Standard Deviation 9.96
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval PR: Week12; n=24, 39	2.2 milliseconds Standard Deviation 10.00	3.0 milliseconds Standard Deviation 9.86
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QRS:Week0; n=80, 80	0.0 milliseconds Standard Deviation 5.75	0.2 milliseconds Standard Deviation 5.60
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QRS: Week4; n=48, 59	0.1 milliseconds Standard Deviation 4.35	-0.8 milliseconds Standard Deviation 5.58
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QRS:Week8; n=33, 47	0.3 milliseconds Standard Deviation 7.03	0.4 milliseconds Standard Deviation 4.86
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QT:Week0; n=80, 80	7.4 milliseconds Standard Deviation 19.67	3.5 milliseconds Standard Deviation 16.69
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QT:Week4; n=48, 59	10.8 milliseconds Standard Deviation 13.32	6.9 milliseconds Standard Deviation 15.63
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QT:Week8; n=33, 47	3.4 milliseconds Standard Deviation 19.22	11.5 milliseconds Standard Deviation 17.57
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QT:Week12; n=24, 39	1.9 milliseconds Standard Deviation 17.17	4.6 milliseconds Standard Deviation 18.77
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QTcFWeek0; n=80, 80	4.2 milliseconds Standard Deviation 12.56	3.8 milliseconds Standard Deviation 11.21
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QTcF:Week4; n=48, 59	5.4 milliseconds Standard Deviation 9.51	2.9 milliseconds Standard Deviation 10.88
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QTcF:Week8; n=33, 47	-0.7 milliseconds Standard Deviation 10.17	6.6 milliseconds Standard Deviation 10.65
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval QTcF:Week12; n=24, 39	1.1 milliseconds Standard Deviation 13.28	2.0 milliseconds Standard Deviation 13.48
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval RR:Week0; n=80, 80	24.0 milliseconds Standard Deviation 104.42	-0.2 milliseconds Standard Deviation 89.38
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval RR:Week4; n=48, 59	37.6 milliseconds Standard Deviation 83.83	29.5 milliseconds Standard Deviation 88.38
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval RR:Week8; n=33, 47	29.3 milliseconds Standard Deviation 97.67	34.4 milliseconds Standard Deviation 95.05
Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval RR:Week12; n=24, 39	8.8 milliseconds Standard Deviation 83.16	20.7 milliseconds Standard Deviation 104.02

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4, 8 and 12

Triplicate 12-lead ECGs were recorded pre-dose and post-dose with participant in semi-supine position after 5 minutes rest. At each time point ECG was taken using an ECG machine that automatically measures heart rate. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=80 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change Between Pre-dose and Post-dose of Heart Rate Week0; n=80, 80	-1.6 Beats per minute Standard Deviation 7.57	0.2 Beats per minute Standard Deviation 6.93
Change Between Pre-dose and Post-dose of Heart Rate Week4; n=48, 59	-2.9 Beats per minute Standard Deviation 5.79	-1.7 Beats per minute Standard Deviation 6.15
Change Between Pre-dose and Post-dose of Heart Rate Week8; n=33, 47	-1.8 Beats per minute Standard Deviation 8.74	-2.3 Beats per minute Standard Deviation 6.83
Change Between Pre-dose and Post-dose of Heart Rate Week12; n=24, 39	-0.2 Beats per minute Standard Deviation 6.69	-0.9 Beats per minute Standard Deviation 7.75

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4, 8 and 12

Triplicate 12-lead ECGs were recorded pre-dose and post-dose with participant in semi-supine position after 5 minutes rest. At each time point ECG was taken using an ECG machine that automatically measures QRS axis. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=80 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change Between Pre-dose and Post-dose of QRS Axis Week0; n=80, 80	-0.8 Degrees Standard Deviation 10.76	1.9 Degrees Standard Deviation 6.75
Change Between Pre-dose and Post-dose of QRS Axis Week4; n=48, 59	-0.3 Degrees Standard Deviation 9.20	-0.9 Degrees Standard Deviation 16.22
Change Between Pre-dose and Post-dose of QRS Axis Week8; n=33, 47	1.2 Degrees Standard Deviation 10.01	-0.2 Degrees Standard Deviation 9.30
Change Between Pre-dose and Post-dose of QRS Axis Week12; n=24, 39	-1.6 Degrees Standard Deviation 6.44	2.8 Degrees Standard Deviation 14.25

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4 and 12

Using a Holter monitor, maximum, minimum and average changes in heart rate was recorded at Baseline, Weeks 0, 4 and 12 through 24 hours. Participants with analyzable time of at least 16 hours were evaluated. Baseline is the value from the screening visit assessment. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=81 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Mean Heart Rate: Week0; n=81, 80	-1.1 Beats per minute Standard Deviation 6.56	-2.0 Beats per minute Standard Deviation 6.00
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Mean Heart Rate: Week4; n=49, 58	76.8 Beats per minute Standard Deviation 10.60	80.0 Beats per minute Standard Deviation 10.80
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Mean Heart Rate: Week12; n=24, 37	78.8 Beats per minute Standard Deviation 11.12	79.9 Beats per minute Standard Deviation 10.08
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Maximum Heart Rate: Week0; n=81, 80	-0.3 Beats per minute Standard Deviation 13.13	-5.0 Beats per minute Standard Deviation 14.55
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Maximum Heart Rate: Week4; n=49, 58	128.3 Beats per minute Standard Deviation 13.03	130.3 Beats per minute Standard Deviation 16.41
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Maximum Heart Rate: Week12; n=24, 37	128.5 Beats per minute Standard Deviation 15.21	132.1 Beats per minute Standard Deviation 15.80
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Minimum Heart Rate: Week0; n=81, 80	-0.8 Beats per minute Standard Deviation 5.08	-0.8 Beats per minute Standard Deviation 4.55
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Minimum Heart Rate: Week4; n=49, 58	50.6 Beats per minute Standard Deviation 7.49	53.8 Beats per minute Standard Deviation 8.15
Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate Minimum Heart Rate: Week12; n=24, 37	53.6 Beats per minute Standard Deviation 7.49	53.4 Beats per minute Standard Deviation 9.09

SECONDARY outcome

Timeframe: Baseline and Weeks 0, 4 and 12

Using a Holter monitor, supraventricular couplets, supraventricular ectopics, supraventricular runs, supraventricular singles, ventricular couplets, ventricular ectopics, ventricular runs, ventricular singles were recorded at Baseline, Weeks 0, 4 and 12 through 24 hours. Participants with analyzable time of at least 16 hours were evaluated. Baseline is the value from the screening visit assessment. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=81 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=80 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular singles: Week0; n=81, 80	9.0 Events per hour Standard Deviation 349.81	-13.1 Events per hour Standard Deviation 120.73
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular singles: Week4; n=49, 58	-25.3 Events per hour Standard Deviation 425.20	-3.1 Events per hour Standard Deviation 138.30
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular runs: Week4; n=49, 58	-0.1 Events per hour Standard Deviation 2.37	-0.6 Events per hour Standard Deviation 3.01
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular runs: Week12; n=24, 37	-1.1 Events per hour Standard Deviation 6.30	-0.4 Events per hour Standard Deviation 1.83
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular singles: Week12; n=24, 37	45.5 Events per hour Standard Deviation 263.03	8.4 Events per hour Standard Deviation 89.64
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular couplets: Week0; n=81, 80	0.7 Events per hour Standard Deviation 3.80	-0.1 Events per hour Standard Deviation 1.59
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular couplets: Week4; n=49, 58	0.2 Events per hour Standard Deviation 0.80	0.1 Events per hour Standard Deviation 0.65
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular couplets: Week12; n=24, 37	0.0 Events per hour Standard Deviation 0.00	0.3 Events per hour Standard Deviation 1.43
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular ectopics: Week0; n=81, 80	44.6 Events per hour Standard Deviation 265.28	-12.2 Events per hour Standard Deviation 141.39
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular ectopics: Week4; n=49, 58	-10.7 Events per hour Standard Deviation 105.24	6.4 Events per hour Standard Deviation 54.80
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular ectopics: Week12; n=24, 37	-5.3 Events per hour Standard Deviation 52.78	176.0 Events per hour Standard Deviation 926.75
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular runs: Week0; n=81, 80	0.0 Events per hour Standard Deviation 0.25	0.0 Events per hour Standard Deviation 0.19
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular runs: Week4; n=49, 58	0.0 Events per hour Standard Deviation 0.29	0.0 Events per hour Standard Deviation 0.00
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular runs: Week12; n=24, 37	0.0 Events per hour Standard Deviation 0.29	0.0 Events per hour Standard Deviation 0.00
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular singles: Week0; n=81, 80	44.0 Events per hour Standard Deviation 228.09	-12.2 Events per hour Standard Deviation 139.28
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular singles: Week4; n=49, 58	-10.4 Events per hour Standard Deviation 104.12	6.3 Events per hour Standard Deviation 53.79
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles ventricular singles: Week12; n=24, 37	-5.4 Events per hour Standard Deviation 53.23	174.5 Events per hour Standard Deviation 921.42
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular couplets: Week0; n=81, 80	-2.0 Events per hour Standard Deviation 21.68	16.5 Events per hour Standard Deviation 144.04
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular couplets: Week4; n=49, 58	-1.9 Events per hour Standard Deviation 14.11	-2.2 Events per hour Standard Deviation 9.86
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular couplets: Week12; n=24, 37	-3.9 Events per hour Standard Deviation 35.82	-0.5 Events per hour Standard Deviation 3.48
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular ectopics: Week0; n=81, 80	2.6 Events per hour Standard Deviation 369.71	6.8 Events per hour Standard Deviation 188.46
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular ectopics: Week4; n=49, 58	-30.9 Events per hour Standard Deviation 445.93	-7.3 Events per hour Standard Deviation 148.20
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular ectopics: Week12; n=24, 37	34.9 Events per hour Standard Deviation 300.07	9.4 Events per hour Standard Deviation 94.82
Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles supraventricular runs: Week0; n=81, 80	-0.5 Events per hour Standard Deviation 3.62	0.2 Events per hour Standard Deviation 2.09

SECONDARY outcome

Timeframe: Baseline and Weeks 2, 4, 8, 12, 16 and 28

Blood samples were collected for the analysis of clinical chemistry parameters including AST, ALT, ALP, GGT and CK at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline and Weeks 2, 4, 8, 12, 16 and 28

Blood samples were collected at given time points to assess clinical chemistry parameters including glucose, potassium, sodium, calcium, Phosphate, chloride, urea and CO2 levels. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline and Weeks 2, 4, 8, 12, 16 and 28

Blood samples were collected for the analysis of clinical chemistry parameters including total bilirubin, creatinine and direct bilirubin at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline and Weeks 2, 4, 8, 12, 16 and 28

Blood samples were collected at given time points to assess clinical chemistry parameters including total protein and albumin levels. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Total Protein: Week 2, n=72, 74	-0.5 Grams per liter Standard Deviation 3.49	0.4 Grams per liter Standard Deviation 3.71
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Total Protein:Week 4, n=47,59	-0.4 Grams per liter Standard Deviation 3.44	-0.4 Grams per liter Standard Deviation 3.76
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Total Protein:Week 8, n=34,47	0.1 Grams per liter Standard Deviation 3.20	0.8 Grams per liter Standard Deviation 3.83
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Total Protein:Week 12, n=24, 36	0.2 Grams per liter Standard Deviation 4.05	-0.6 Grams per liter Standard Deviation 4.79
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Total Protein:Week 16, n=24, 39	0.5 Grams per liter Standard Deviation 4.33	0.4 Grams per liter Standard Deviation 3.34
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Total Protein:Week 28, n=74, 73	-0.8 Grams per liter Standard Deviation 4.04	-0.2 Grams per liter Standard Deviation 4.27
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Albumin: Week 2, n=72, 74	-0.5 Grams per liter Standard Deviation 2.38	-0.4 Grams per liter Standard Deviation 2.11
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Albumin:Week 4, n=47,59	-0.5 Grams per liter Standard Deviation 2.29	-0.8 Grams per liter Standard Deviation 2.62
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Albumin:Week 8, n=34,47	-0.4 Grams per liter Standard Deviation 2.36	0.0 Grams per liter Standard Deviation 2.38
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Albumin:Week 12, n=24, 36	-0.3 Grams per liter Standard Deviation 2.40	-0.9 Grams per liter Standard Deviation 2.69
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Albumin:Week 16, n=24, 39	-0.1 Grams per liter Standard Deviation 2.82	-0.4 Grams per liter Standard Deviation 2.25
Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin Albumin:Week 28, n=74, 73	-0.6 Grams per liter Standard Deviation 2.70	-0.6 Grams per liter Standard Deviation 2.99

SECONDARY outcome

Timeframe: Baseline and Weeks1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected at given time points to assess hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, leutrophils, monocytes, and platelets . Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline and Weeks1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Population: Safety Population. Only those participants with data available at indicated time points were analyzed . Participants with data available at specified time points were represented by n=x in the category titles.

Blood samples were collected for the analysis of erythrocyte mean corpuscular volume at indicated time points.Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 14: n=24, 39	-0.7 Femtoliters Standard Deviation 1.63	-1.5 Femtoliters Standard Deviation 2.46
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 1: n=78,74	0.3 Femtoliters Standard Deviation 1.59	-0.1 Femtoliters Standard Deviation 1.46
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 2: n=71, 74	0.2 Femtoliters Standard Deviation 1.44	-0.2 Femtoliters Standard Deviation 1.62
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 4: n=49, 57	-0.4 Femtoliters Standard Deviation 1.62	-0.6 Femtoliters Standard Deviation 1.98
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 6: n=44, 56	-0.3 Femtoliters Standard Deviation 1.29	-0.4 Femtoliters Standard Deviation 2.33
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 8: n=34, 47	-0.9 Femtoliters Standard Deviation 1.37	-0.6 Femtoliters Standard Deviation 2.13
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 10: n=34, 45	-1.1 Femtoliters Standard Deviation 1.82	-0.9 Femtoliters Standard Deviation 2.52
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 12: n=24, 39	-0.7 Femtoliters Standard Deviation 1.46	-1.3 Femtoliters Standard Deviation 2.61
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 16: n=24, 39	-0.6 Femtoliters Standard Deviation 1.58	-2.3 Femtoliters Standard Deviation 2.67
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume Week 28: n=65, 63	-1.6 Femtoliters Standard Deviation 2.76	-2.9 Femtoliters Standard Deviation 5.20

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of erythrocytes at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Erythrocytes Week 2: n=71, 74	0.01 10^12 cells per liter Standard Deviation 0.232	0.01 10^12 cells per liter Standard Deviation 0.200
Change From Baseline in Hematology Parameter: Erythrocytes Week 8: n=34, 47	0.02 10^12 cells per liter Standard Deviation 0.210	0.02 10^12 cells per liter Standard Deviation 0.234
Change From Baseline in Hematology Parameter: Erythrocytes Week 10: n=34, 45	0.00 10^12 cells per liter Standard Deviation 0.228	-0.02 10^12 cells per liter Standard Deviation 0.201
Change From Baseline in Hematology Parameter: Erythrocytes Week 12: n=24, 39	0.06 10^12 cells per liter Standard Deviation 0.226	-0.03 10^12 cells per liter Standard Deviation 0.297
Change From Baseline in Hematology Parameter: Erythrocytes Week 16: n=24, 39	0.00 10^12 cells per liter Standard Deviation 0.184	0.03 10^12 cells per liter Standard Deviation 0.236
Change From Baseline in Hematology Parameter: Erythrocytes Week 28: n=65, 63	0.09 10^12 cells per liter Standard Deviation 0.260	0.09 10^12 cells per liter Standard Deviation 0.381
Change From Baseline in Hematology Parameter: Erythrocytes Week 1: n=78,74	-0.01 10^12 cells per liter Standard Deviation 0.220	-0.03 10^12 cells per liter Standard Deviation 0.232
Change From Baseline in Hematology Parameter: Erythrocytes Week 4: n=49, 57	0.05 10^12 cells per liter Standard Deviation 0.298	-0.01 10^12 cells per liter Standard Deviation 0.169
Change From Baseline in Hematology Parameter: Erythrocytes Week 6: n=44, 56	0.05 10^12 cells per liter Standard Deviation 0.181	-0.04 10^12 cells per liter Standard Deviation 0.170
Change From Baseline in Hematology Parameter: Erythrocytes Week 14: n=24, 39	0.03 10^12 cells per liter Standard Deviation 0.206	0.04 10^12 cells per liter Standard Deviation 0.253

SECONDARY outcome

Timeframe: Baseline and Weeks1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of hemoglobin level at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Hemoglobin Week 1: n=78,74	0.5 Grams per liter Standard Deviation 7.08	-0.7 Grams per liter Standard Deviation 6.30
Change From Baseline in Hematology Parameter: Hemoglobin Week 2: n=71, 74	0.5 Grams per liter Standard Deviation 7.01	0.0 Grams per liter Standard Deviation 5.64
Change From Baseline in Hematology Parameter: Hemoglobin Week 4: n=49, 57	1.6 Grams per liter Standard Deviation 8.84	-0.4 Grams per liter Standard Deviation 5.16
Change From Baseline in Hematology Parameter: Hemoglobin Week 6: n=44, 56	1.5 Grams per liter Standard Deviation 4.60	-1.2 Grams per liter Standard Deviation 5.17
Change From Baseline in Hematology Parameter: Hemoglobin Week 8: n=34, 47	0.5 Grams per liter Standard Deviation 6.16	-0.1 Grams per liter Standard Deviation 6.72
Change From Baseline in Hematology Parameter: Hemoglobin Week 10: n=34, 45	-0.4 Grams per liter Standard Deviation 5.71	-0.8 Grams per liter Standard Deviation 5.28
Change From Baseline in Hematology Parameter: Hemoglobin Week 12: n=24, 39	1.0 Grams per liter Standard Deviation 6.50	-1.8 Grams per liter Standard Deviation 10.05
Change From Baseline in Hematology Parameter: Hemoglobin Week 14: n=24, 39	-0.6 Grams per liter Standard Deviation 6.08	-0.3 Grams per liter Standard Deviation 6.35
Change From Baseline in Hematology Parameter: Hemoglobin Week 16: n=24, 39	-0.5 Grams per liter Standard Deviation 5.44	0.0 Grams per liter Standard Deviation 6.14
Change From Baseline in Hematology Parameter: Hemoglobin Week 28: n=65, 63	1.0 Grams per liter Standard Deviation 8.20	-0.7 Grams per liter Standard Deviation 10.24

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of hematocrit at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Hematocrit Level Week 1: n=78,74	0.0007 Proportion of red blood cells in blood Standard Deviation 0.02255	-0.0025 Proportion of red blood cells in blood Standard Deviation 0.02114
Change From Baseline in Hematology Parameter: Hematocrit Level Week 2: n=71, 74	0.0024 Proportion of red blood cells in blood Standard Deviation 0.02213	-0.0046 Proportion of red blood cells in blood Standard Deviation 0.04223
Change From Baseline in Hematology Parameter: Hematocrit Level Week 4: n=49, 57	0.0038 Proportion of red blood cells in blood Standard Deviation 0.02957	-0.0033 Proportion of red blood cells in blood Standard Deviation 0.01665
Change From Baseline in Hematology Parameter: Hematocrit Level Week 6: n=44, 56	0.0024 Proportion of red blood cells in blood Standard Deviation 0.01557	-0.0050 Proportion of red blood cells in blood Standard Deviation 0.02060
Change From Baseline in Hematology Parameter: Hematocrit Level Week 8: n=34, 47	-0.0019 Proportion of red blood cells in blood Standard Deviation 0.01645	-0.0015 Proportion of red blood cells in blood Standard Deviation 0.02212
Change From Baseline in Hematology Parameter: Hematocrit Level Week 10: n=34, 45	-0.0050 Proportion of red blood cells in blood Standard Deviation 0.01897	-0.0061 Proportion of red blood cells in blood Standard Deviation 0.02175
Change From Baseline in Hematology Parameter: Hematocrit Level Week 12: n=24, 39	0.0009 Proportion of red blood cells in blood Standard Deviation 0.01740	-0.0088 Proportion of red blood cells in blood Standard Deviation 0.03342
Change From Baseline in Hematology Parameter: Hematocrit Level Week 14: n=24, 39	-0.0018 Proportion of red blood cells in blood Standard Deviation 0.01699	-0.0038 Proportion of red blood cells in blood Standard Deviation 0.02277
Change From Baseline in Hematology Parameter: Hematocrit Level Week 16: n=24, 39	-0.0042 Proportion of red blood cells in blood Standard Deviation 0.01474	-0.0071 Proportion of red blood cells in blood Standard Deviation 0.02232
Change From Baseline in Hematology Parameter: Hematocrit Level Week 28: n=65, 63	0.0016 Proportion of red blood cells in blood Standard Deviation 0.02283	-0.0041 Proportion of red blood cells in blood Standard Deviation 0.03153

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of mean corpuscular hemoglobin at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 4: n=49, 57	0.01 Picogram Standard Deviation 0.461	-0.04 Picogram Standard Deviation 0.432
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 6: n=44, 56	0.06 Picogram Standard Deviation 0.416	0.00 Picogram Standard Deviation 0.551
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 10: n=34, 45	-0.06 Picogram Standard Deviation 0.590	-0.01 Picogram Standard Deviation 0.863
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 1: n=78,74	0.17 Picogram Standard Deviation 0.725	0.01 Picogram Standard Deviation 0.453
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 2: n=71, 74	0.01 Picogram Standard Deviation 0.430	-0.07 Picogram Standard Deviation 0.471
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 8: n=34, 47	0.02 Picogram Standard Deviation 0.660	-0.11 Picogram Standard Deviation 0.567
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 12: n=24, 39	-0.07 Picogram Standard Deviation 0.543	-0.12 Picogram Standard Deviation 0.776
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 14: n=24, 39	-0.23 Picogram Standard Deviation 0.421	-0.29 Picogram Standard Deviation 0.785
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 16: n=24, 39	-0.05 Picogram Standard Deviation 0.475	-0.26 Picogram Standard Deviation 0.839
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Week 28: n=65, 63	-0.40 Picogram Standard Deviation 0.649	-0.78 Picogram Standard Deviation 1.773

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of mean corpuscular hemoglobin concentration at indicated time points.Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 4: n=49, 57	1.2 Grams per liter Standard Deviation 7.01	1.5 Grams per liter Standard Deviation 7.32
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 1: n=78,74	0.8 Grams per liter Standard Deviation 8.29	0.5 Grams per liter Standard Deviation 6.65
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 2: n=71, 74	-0.6 Grams per liter Standard Deviation 6.04	0.2 Grams per liter Standard Deviation 7.09
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 6: n=44, 56	1.9 Grams per liter Standard Deviation 5.33	1.3 Grams per liter Standard Deviation 9.33
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 8: n=34, 47	3.0 Grams per liter Standard Deviation 7.65	1.1 Grams per liter Standard Deviation 7.56
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 10: n=34, 45	3.3 Grams per liter Standard Deviation 6.68	3.4 Grams per liter Standard Deviation 10.17
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 12: n=24, 39	2.3 Grams per liter Standard Deviation 6.29	3.2 Grams per liter Standard Deviation 10.32
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 14: n=24, 39	0.4 Grams per liter Standard Deviation 6.47	2.4 Grams per liter Standard Deviation 8.97
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 16: n=24, 39	2.1 Grams per liter Standard Deviation 7.01	5.7 Grams per liter Standard Deviation 9.60
Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration Week 28: n=65, 63	1.2 Grams per liter Standard Deviation 8.36	1.5 Grams per liter Standard Deviation 8.78

SECONDARY outcome

Timeframe: Baseline and Weeks1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of Erythrocytes Distribution Width (%) at indicated time points. Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 8: n=34, 47	-0.40 Percentage (%) of Erythrocytes Standard Deviation 0.669	-0.29 Percentage (%) of Erythrocytes Standard Deviation 0.960
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 1: n=78,74	-0.06 Percentage (%) of Erythrocytes Standard Deviation 0.747	-0.08 Percentage (%) of Erythrocytes Standard Deviation 0.604
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 2: n=71, 74	-0.02 Percentage (%) of Erythrocytes Standard Deviation 0.478	-0.20 Percentage (%) of Erythrocytes Standard Deviation 0.652
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 4: n=49, 57	-0.22 Percentage (%) of Erythrocytes Standard Deviation 0.555	-0.33 Percentage (%) of Erythrocytes Standard Deviation 0.844
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 6: n=44, 56	-0.33 Percentage (%) of Erythrocytes Standard Deviation 0.545	-0.37 Percentage (%) of Erythrocytes Standard Deviation 0.861
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 10: n=34, 45	-0.35 Percentage (%) of Erythrocytes Standard Deviation 0.791	-0.38 Percentage (%) of Erythrocytes Standard Deviation 1.049
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 12: n=24, 39	-0.27 Percentage (%) of Erythrocytes Standard Deviation 0.717	-0.34 Percentage (%) of Erythrocytes Standard Deviation 0.916
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 14: n=24, 39	-0.28 Percentage (%) of Erythrocytes Standard Deviation 0.873	-0.38 Percentage (%) of Erythrocytes Standard Deviation 0.897
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 16: n=24, 39	-0.25 Percentage (%) of Erythrocytes Standard Deviation 0.727	-0.41 Percentage (%) of Erythrocytes Standard Deviation 0.995
Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%) Week 28: n=65, 63	-0.09 Percentage (%) of Erythrocytes Standard Deviation 1.028	-0.01 Percentage (%) of Erythrocytes Standard Deviation 1.202

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of N-Terminal ProB-type Natriuretic Peptide at indicated time points.Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=79 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=75 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 1: n=79,75	-14.8442 Nanograms per liter Standard Deviation 61.92992	8.4023 Nanograms per liter Standard Deviation 54.37938
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 2: n=73,75	-10.8134 Nanograms per liter Standard Deviation 71.40009	-2.5196 Nanograms per liter Standard Deviation 42.06499
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 4: n=49, 59	-17.9849 Nanograms per liter Standard Deviation 68.85651	-4.5560 Nanograms per liter Standard Deviation 44.12297
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 6: n=45, 57	-5.0620 Nanograms per liter Standard Deviation 53.06025	3.6194 Nanograms per liter Standard Deviation 53.96329
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 8: n=34, 47	-8.6398 Nanograms per liter Standard Deviation 49.58134	9.6509 Nanograms per liter Standard Deviation 66.34546
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 10: n=34, 46	-12.7377 Nanograms per liter Standard Deviation 80.51666	14.9119 Nanograms per liter Standard Deviation 58.17102
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 12: n=24, 38	-13.6951 Nanograms per liter Standard Deviation 53.70314	8.8531 Nanograms per liter Standard Deviation 58.15689
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 14: n=24, 39	-4.8082 Nanograms per liter Standard Deviation 57.47926	20.0149 Nanograms per liter Standard Deviation 74.94234
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 16: n=24, 39	-19.4899 Nanograms per liter Standard Deviation 58.89689	4.7760 Nanograms per liter Standard Deviation 60.56438
Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide Week 28: n=65, 65	-6.1970 Nanograms per liter Standard Deviation 62.26132	0.9810 Nanograms per liter Standard Deviation 64.44446

SECONDARY outcome

Timeframe: Baseline and Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16 and 28

Blood samples were collected for the analysis of Troponin I at indicated time points.Baseline is defined as the most recent recorded value before dosing on Day 1. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 1: n=78,74	0.000 Micrograms per liter Standard Deviation 0.0000	0.000 Micrograms per liter Standard Deviation 0.0023
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 2: n=73, 73	0.000 Micrograms per liter Standard Deviation 0.0016	0.000 Micrograms per liter Standard Deviation 0.0023
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 4: n=49, 58	0.001 Micrograms per liter Standard Deviation 0.0059	0.000 Micrograms per liter Standard Deviation 0.0000
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 6: n=45, 57	0.000 Micrograms per liter Standard Deviation 0.0021	0.000 Micrograms per liter Standard Deviation 0.0000
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 8: n=34, 46	0.000 Micrograms per liter Standard Deviation 0.0017	0.000 Micrograms per liter Standard Deviation 0.0000
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 10: n=34, 38	0.006 Micrograms per liter Standard Deviation 0.0344	0.000 Micrograms per liter Standard Deviation 0.0000
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 12: n=24, 39	0.000 Micrograms per liter Standard Deviation 0.0000	0.000 Micrograms per liter Standard Deviation 0.0000
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 14: n=24, 39	0.000 Micrograms per liter Standard Deviation 0.0000	0.000 Micrograms per liter Standard Deviation 0.0016
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 16: n=24, 39	0.000 Micrograms per liter Standard Deviation 0.0000	0.000 Micrograms per liter Standard Deviation 0.0000
Change From Baseline in Cardiac Marker: Cardiac Troponin I Week 28: n=63, 63	0.000 Micrograms per liter Standard Deviation 0.0013	-0.001 Micrograms per liter Standard Deviation 0.0050

SECONDARY outcome

Timeframe: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24 and 28

Blood samples were collected at given time points and the presence of anti-GSK3772847 antibodies were assessed using a a tiered approach including a screening assay, a confirmation assay and calculation of titer. Data for participants who showed positive results for confirmation assay has been presented

Outcome measures

Outcome measures
Measure	Placebo n=74 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=75 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week2; n=73, 74	0 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week4; n=49, 59	0 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week8; n=34, 47	0 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week12; n=24, 39	0 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week16; n=23, 39	0 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week20; n=73, 75	1 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week24; n=74, 75	0 Participants	0 Participants
Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies Week28; n=74, 74	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Weeks 2, 4 (Pre-dose), 8 (Pre-dose), 12 (Pre-dose and Post-dose), 16, 20, 24 and 28

Population: PK Population consists of all randomized participants who received at least one dose of study medication, and for whom at least one pharmacokinetic sample was obtained, analyzed and was measurable. Participants with data available at specified time points were represented by n=x in the category titles.

Blood samples were collected at given time points to evaluate pharmacokinetics (PK) of GSK3772847 in participants with moderately severe asthma.

Outcome measures

Outcome measures
Measure	Placebo n=75 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Serum Concentrations of GSK3772847 Week2; n=75	78.40 Micrograms per milliliter Standard Deviation 30.934	—
Serum Concentrations of GSK3772847 Week4; Pre-dose;n=59	44.42 Micrograms per milliliter Standard Deviation 21.774	—
Serum Concentrations of GSK3772847 Week8; Pre-dose; n= 47	61.44 Micrograms per milliliter Standard Deviation 30.978	—
Serum Concentrations of GSK3772847 Week12; Pre-dose; n=39	63.42 Micrograms per milliliter Standard Deviation 34.420	—
Serum Concentrations of GSK3772847 Week12; Post-dose; n=39	224.21 Micrograms per milliliter Standard Deviation 151.780	—
Serum Concentrations of GSK3772847 Week16; n=38	63.03 Micrograms per milliliter Standard Deviation 36.328	—
Serum Concentrations of GSK3772847 Week20; n=75	25.75 Micrograms per milliliter Standard Deviation 19.074	—
Serum Concentrations of GSK3772847 Week24; n=75	12.91 Micrograms per milliliter Standard Deviation 16.061	—
Serum Concentrations of GSK3772847 Week28; n=75	6.14 Micrograms per milliliter Standard Deviation 16.005	—

SECONDARY outcome

Timeframe: Baseline and Week 4 (Pre-dose), Week 8 (Pre-dose), Week 12 (Pre-dose) and Week 16

Blood samples were collected at given time points to measure free soluble ST2 concentration. Baseline is defined as the latest available assessment prior to first dose (Day 1). Analysis was performed using mixed model repeated measures. Percent change from Baseline is calculated as ratio to Baseline minus 1 and multiplied by 100.

Outcome measures

Outcome measures
Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=78 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percent Change From Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration Week12; Pre-dose; n=23, 37	10.5 Percent change Interval -17.4 to 47.7	-92.5 Percent change Interval -94.2 to -90.4
Percent Change From Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration Week4; Pre-dose; n=48, 56	-5.6 Percent change Interval -20.8 to 12.4	-93.8 Percent change Interval -94.7 to -92.7
Percent Change From Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration Week8; Pre-dose; n=33, 45	-8.5 Percent change Interval -26.9 to 14.5	-93.5 Percent change Interval -94.7 to -92.0
Percent Change From Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration Week16; n=16, 26	19.8 Percent change Interval -8.8 to 57.3	-92.0 Percent change Interval -93.7 to -89.9

SECONDARY outcome

Timeframe: Baseline and Week 4 (Pre-dose), Week 8 (Pre-dose), Week 12 (Pre-dose) and Week 16

Blood samples were collected at given time points to measure total soluble ST2 concentration. Baseline is defined as the latest available assessment prior to first dose (Day 1). Analysis was performed using mixed model repeated measures. Percent change from Baseline is calculated as ratio to Baseline minus 1 and multiplied by 100.

Outcome measures

Outcome measures
Measure	Placebo n=48 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=56 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Percent Change From Baseline in Total Soluble ST2 Concentration Week4; Pre-dose; n=48, 56	16.3 Percent change Interval -0.6 to 36.0	2691.1 Percent change Interval 2314.4 to 3126.6
Percent Change From Baseline in Total Soluble ST2 Concentration Week8; Pre-dose; n=33, 45	-6.9 Percent change Interval -22.7 to 12.0	2326.9 Percent change Interval 1951.7 to 2770.7
Percent Change From Baseline in Total Soluble ST2 Concentration Week12; Pre-dose; n=23, 37	-13.4 Percent change Interval -33.4 to 12.6	1858.0 Percent change Interval 1461.4 to 2355.2
Percent Change From Baseline in Total Soluble ST2 Concentration Week16; n=16, 26	-12.0 Percent change Interval -28.5 to 8.3	2330.8 Percent change Interval 1933.0 to 2806.4

Adverse Events

Placebo

Serious events: 1 serious events

Other events: 20 other events

Deaths: 0 deaths

GSK3772847

Serious events: 2 serious events

Other events: 19 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo n=82 participants at risk Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 participants at risk Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Immune system disorders Anaphylactic shock	0.00% 0/82 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	1.2% 1/83 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Infections and infestations Pneumonia	1.2% 1/82 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	0.00% 0/83 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/82 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	1.2% 1/83 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.

Other adverse events

Other adverse events
Measure	Placebo n=82 participants at risk Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 participants at risk Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Infections and infestations Nasopharyngitis	4.9% 4/82 • Number of events 5 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	4.8% 4/83 • Number of events 6 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Infections and infestations Influenza	4.9% 4/82 • Number of events 4 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	1.2% 1/83 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Infections and infestations Upper respiratory tract infection	1.2% 1/82 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	4.8% 4/83 • Number of events 5 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Nervous system disorders Headache	11.0% 9/82 • Number of events 15 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	10.8% 9/83 • Number of events 17 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Musculoskeletal and connective tissue disorders Arthralgia	1.2% 1/82 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	4.8% 4/83 • Number of events 5 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Cardiac disorders Ventricular tachycardia	3.7% 3/82 • Number of events 3 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	1.2% 1/83 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.
Respiratory, thoracic and mediastinal disorders Cough	1.2% 1/82 • Number of events 1 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.	3.6% 3/83 • Number of events 3 • SAEs and non-SAEs were collected for 16 weeks. SAEs and non-SAEs were reported for Safety Population. The non-SAEs were reported using a frequency threshold of \>=3%.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Placebo n=82 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=83 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Post-dose: Week0; n=82, 83	-2.0 Millimeters of Mercury (mmHg) Standard Deviation 8.05	1.3 Millimeters of Mercury (mmHg) Standard Deviation 7.19
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week1; n=79, 75	-0.9 Millimeters of Mercury (mmHg) Standard Deviation 9.61	0.4 Millimeters of Mercury (mmHg) Standard Deviation 9.67
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week2; n=73, 75	-1.3 Millimeters of Mercury (mmHg) Standard Deviation 10.73	-1.3 Millimeters of Mercury (mmHg) Standard Deviation 10.58
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Pre-dose: Week4; n=49, 59	-2.0 Millimeters of Mercury (mmHg) Standard Deviation 8.88	-0.1 Millimeters of Mercury (mmHg) Standard Deviation 8.84
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Post-dose: Week4; n=48, 59	-2.0 Millimeters of Mercury (mmHg) Standard Deviation 9.46	2.2 Millimeters of Mercury (mmHg) Standard Deviation 10.72
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP:Week6; n=45, 57	-1.7 Millimeters of Mercury (mmHg) Standard Deviation 9.33	0.9 Millimeters of Mercury (mmHg) Standard Deviation 9.38
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Pre-Dose:Week8; n=34, 47	-1.9 Millimeters of Mercury (mmHg) Standard Deviation 7.85	0.4 Millimeters of Mercury (mmHg) Standard Deviation 7.91
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Post-DoseWeek8; n=34, 47	-2.7 Millimeters of Mercury (mmHg) Standard Deviation 9.81	2.3 Millimeters of Mercury (mmHg) Standard Deviation 9.46
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week10; n=34, 46	-2.5 Millimeters of Mercury (mmHg) Standard Deviation 10.20	0.7 Millimeters of Mercury (mmHg) Standard Deviation 11.74
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Pre-dose: Week12; n=24, 39	0.3 Millimeters of Mercury (mmHg) Standard Deviation 8.34	1.5 Millimeters of Mercury (mmHg) Standard Deviation 10.19
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Post-dose: Week12; n=24, 39	-0.7 Millimeters of Mercury (mmHg) Standard Deviation 6.34	3.3 Millimeters of Mercury (mmHg) Standard Deviation 11.23
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week14; n=24, 39	-1.6 Millimeters of Mercury (mmHg) Standard Deviation 9.17	2.1 Millimeters of Mercury (mmHg) Standard Deviation 10.47
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week16; n=24, 39	-2.8 Millimeters of Mercury (mmHg) Standard Deviation 9.16	1.5 Millimeters of Mercury (mmHg) Standard Deviation 10.37
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week20; n=76, 78	-1.0 Millimeters of Mercury (mmHg) Standard Deviation 10.72	1.7 Millimeters of Mercury (mmHg) Standard Deviation 10.32
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week24; n=75, 76	-2.4 Millimeters of Mercury (mmHg) Standard Deviation 10.78	1.7 Millimeters of Mercury (mmHg) Standard Deviation 10.46
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP: Week28; n=74, 77	-1.3 Millimeters of Mercury (mmHg) Standard Deviation 9.95	1.0 Millimeters of Mercury (mmHg) Standard Deviation 9.77
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Post-dose: Week0; n=82,83	-0.7 Millimeters of Mercury (mmHg) Standard Deviation 6.58	-0.3 Millimeters of Mercury (mmHg) Standard Deviation 5.67
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week1; n=79, 75	0.3 Millimeters of Mercury (mmHg) Standard Deviation 6.96	0.7 Millimeters of Mercury (mmHg) Standard Deviation 8.29
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week2; n=73, 75	-0.7 Millimeters of Mercury (mmHg) Standard Deviation 8.61	-0.8 Millimeters of Mercury (mmHg) Standard Deviation 7.04
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Pre-dose: Week4; n=49, 59	-1.1 Millimeters of Mercury (mmHg) Standard Deviation 8.26	0.4 Millimeters of Mercury (mmHg) Standard Deviation 7.72
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Post-dose: Week4; n=48, 59	-0.4 Millimeters of Mercury (mmHg) Standard Deviation 7.93	0.3 Millimeters of Mercury (mmHg) Standard Deviation 7.79
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP:Week6; n=45, 57	0.6 Millimeters of Mercury (mmHg) Standard Deviation 7.72	-1.0 Millimeters of Mercury (mmHg) Standard Deviation 7.32
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Pre-Dose:Week8; n=34, 47	-0.4 Millimeters of Mercury (mmHg) Standard Deviation 7.66	-2.0 Millimeters of Mercury (mmHg) Standard Deviation 7.79
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Post-DoseWeek8; n=34, 47	-0.1 Millimeters of Mercury (mmHg) Standard Deviation 7.54	-1.2 Millimeters of Mercury (mmHg) Standard Deviation 7.21
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week10; n=34, 46	-0.1 Millimeters of Mercury (mmHg) Standard Deviation 9.36	-0.2 Millimeters of Mercury (mmHg) Standard Deviation 7.94
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Pre-dose: Week12; n=24, 39	0.3 Millimeters of Mercury (mmHg) Standard Deviation 7.27	0.6 Millimeters of Mercury (mmHg) Standard Deviation 6.52
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Post-dose: Week12; n=24, 39	0.0 Millimeters of Mercury (mmHg) Standard Deviation 8.08	-0.5 Millimeters of Mercury (mmHg) Standard Deviation 6.79
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week14; n=24, 39	0.0 Millimeters of Mercury (mmHg) Standard Deviation 5.28	0.5 Millimeters of Mercury (mmHg) Standard Deviation 6.84
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week16; n=24, 39	-0.3 Millimeters of Mercury (mmHg) Standard Deviation 8.37	-0.5 Millimeters of Mercury (mmHg) Standard Deviation 5.59
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week20; n=76, 78	-0.4 Millimeters of Mercury (mmHg) Standard Deviation 8.61	0.7 Millimeters of Mercury (mmHg) Standard Deviation 6.60
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week24; n=75, 76	0.1 Millimeters of Mercury (mmHg) Standard Deviation 8.15	0.3 Millimeters of Mercury (mmHg) Standard Deviation 7.06
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP: Week28; n=74, 77	-0.3 Millimeters of Mercury (mmHg) Standard Deviation 9.74	-0.4 Millimeters of Mercury (mmHg) Standard Deviation 7.62

Measure	Placebo n=74 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) AST:Week 16, n=24, 39	-1.4 International units per liter Standard Deviation 6.01	-3.3 International units per liter Standard Deviation 6.70
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) AST:Week 28, n=74, 74	-2.3 International units per liter Standard Deviation 6.96	-1.7 International units per liter Standard Deviation 8.64
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) CK: Week 2, n=72, 74	-12.5 International units per liter Standard Deviation 92.00	-18.8 International units per liter Standard Deviation 207.72
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) CK:Week 4, n=47,59	-30.3 International units per liter Standard Deviation 68.86	-45.1 International units per liter Standard Deviation 231.07
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) CK:Week 8, n=34,47	-26.6 International units per liter Standard Deviation 57.01	-32.9 International units per liter Standard Deviation 242.98
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) CK:Week 12, n=24, 36	-5.0 International units per liter Standard Deviation 73.56	-54.5 International units per liter Standard Deviation 282.17
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) CK:Week 16, n=24, 39	-20.8 International units per liter Standard Deviation 81.02	-46.8 International units per liter Standard Deviation 272.08
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) CK:Week 28, n=74, 74	-8.5 International units per liter Standard Deviation 131.56	-30.7 International units per liter Standard Deviation 199.41
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) GGT: Week 2, n=72, 74	-3.2 International units per liter Standard Deviation 9.61	-1.2 International units per liter Standard Deviation 12.16
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) GGT:Week 4, n=47,59	-3.9 International units per liter Standard Deviation 14.00	-2.5 International units per liter Standard Deviation 21.35
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) GGT:Week 8, n=34,47	-3.5 International units per liter Standard Deviation 13.50	-2.8 International units per liter Standard Deviation 15.61
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) GGT:Week 12, 24, 36	-0.3 International units per liter Standard Deviation 5.87	-5.4 International units per liter Standard Deviation 19.48
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) GGT:Week 16, n=24, 39	-1.1 International units per liter Standard Deviation 4.41	-3.9 International units per liter Standard Deviation 14.64
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) GGT:Week 28, n=74, 73	-3.2 International units per liter Standard Deviation 13.80	-0.7 International units per liter Standard Deviation 16.06
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) AST:Week 8, n=34,47	-1.6 International units per liter Standard Deviation 6.58	-2.7 International units per liter Standard Deviation 6.36
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALP:Week 16; n=24, 39	1.0 International units per liter Standard Deviation 9.33	-2.3 International units per liter Standard Deviation 9.75
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALP:Week 28; n=74, 74	-0.4 International units per liter Standard Deviation 12.33	-1.2 International units per liter Standard Deviation 13.25
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) AST:Week 12, n=24, 36	-1.8 International units per liter Standard Deviation 4.91	-4.1 International units per liter Standard Deviation 6.59
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) AST: Week 2; n=72, 74	-0.8 International units per liter Standard Deviation 9.30	-1.5 International units per liter Standard Deviation 6.59
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) AST:Week 4; n=47,59	-1.0 International units per liter Standard Deviation 6.02	-2.5 International units per liter Standard Deviation 6.75
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALT: Week 2; n=72, 74	-0.9 International units per liter Standard Deviation 8.88	-0.2 International units per liter Standard Deviation 7.07
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALT:Week 4; n=47,59	-0.5 International units per liter Standard Deviation 9.50	-2.6 International units per liter Standard Deviation 7.24
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALT: Week 8; n=34,47	-0.1 International units per liter Standard Deviation 6.93	-2.4 International units per liter Standard Deviation 7.30
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALT: Week 12; n=24, 36	-1.6 International units per liter Standard Deviation 6.86	-2.4 International units per liter Standard Deviation 7.77
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALT: Week 16; n=24, 39	-1.2 International units per liter Standard Deviation 7.97	-2.6 International units per liter Standard Deviation 6.54
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALT: Week 28; n=74, 74	-1.1 International units per liter Standard Deviation 9.57	-0.9 International units per liter Standard Deviation 10.51
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALP: Week 2; n=72, 74	-1.9 International units per liter Standard Deviation 8.32	-0.8 International units per liter Standard Deviation 8.96
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALP:Week 4; n=47, 59	-0.8 International units per liter Standard Deviation 13.18	-1.0 International units per liter Standard Deviation 8.17
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALP:Week 8; n=34, 47	0.9 International units per liter Standard Deviation 7.37	-2.3 International units per liter Standard Deviation 8.64
Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK) ALP:Week 12; n =24, 36	2.4 International units per liter Standard Deviation 8.79	-3.0 International units per liter Standard Deviation 14.01

Measure	Placebo n=74 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Phosphate:Week 12; n=24, 36	0.025 Millimoles per liter Standard Deviation 0.1133	-0.013 Millimoles per liter Standard Deviation 0.1495
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Phosphate:Week 28; n=74, 73	-0.013 Millimoles per liter Standard Deviation 0.1854	-0.018 Millimoles per liter Standard Deviation 0.1743
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Chloride: Week 2; n=72, 74	0.3 Millimoles per liter Standard Deviation 2.47	0.1 Millimoles per liter Standard Deviation 2.22
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Glucose: Week 2; n=72, 74	0.13 Millimoles per liter Standard Deviation 0.996	0.05 Millimoles per liter Standard Deviation 1.273
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Glucose:Week 4; n=47,59	0.18 Millimoles per liter Standard Deviation 0.784	0.19 Millimoles per liter Standard Deviation 1.156
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Glucose:Week 8; n=34,47	0.26 Millimoles per liter Standard Deviation 1.008	0.00 Millimoles per liter Standard Deviation 1.400
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Glucose:Week 12; n=24, 36	-0.04 Millimoles per liter Standard Deviation 0.796	0.20 Millimoles per liter Standard Deviation 1.516
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Glucose:Week 16; n=24, 39	-0.10 Millimoles per liter Standard Deviation 1.057	0.12 Millimoles per liter Standard Deviation 0.984
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Glucose:Week 28; n=74, 73	0.30 Millimoles per liter Standard Deviation 1.245	0.04 Millimoles per liter Standard Deviation 1.780
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Potassium: Week 2; n=72, 74	0.14 Millimoles per liter Standard Deviation 0.366	0.13 Millimoles per liter Standard Deviation 0.596
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Potassium:Week 4; n=47,59	0.04 Millimoles per liter Standard Deviation 0.361	0.05 Millimoles per liter Standard Deviation 0.402
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Potassium:Week 8; n=34,47	-0.01 Millimoles per liter Standard Deviation 0.352	-0.04 Millimoles per liter Standard Deviation 0.397
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Potassium:Week 12; n=24, 36	0.02 Millimoles per liter Standard Deviation 0.363	0.00 Millimoles per liter Standard Deviation 0.439
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Potassium:Week 16; n=24, 39	-0.09 Millimoles per liter Standard Deviation 0.403	0.00 Millimoles per liter Standard Deviation 0.439
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Potassium:Week 28; n=74, 73	0.01 Millimoles per liter Standard Deviation 0.407	0.01 Millimoles per liter Standard Deviation 0.416
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Sodium: Week 2; n=72, 74	0.3 Millimoles per liter Standard Deviation 2.19	-0.1 Millimoles per liter Standard Deviation 2.31
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Sodium:Week 4; n=47,59	0.0 Millimoles per liter Standard Deviation 1.65	-0.9 Millimoles per liter Standard Deviation 2.34
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Sodium:Week 8; n=34,47	-0.1 Millimoles per liter Standard Deviation 1.41	-0.6 Millimoles per liter Standard Deviation 1.51
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Sodium:Week 12; n=24, 36	-0.3 Millimoles per liter Standard Deviation 2.17	-1.1 Millimoles per liter Standard Deviation 1.71
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Sodium:Week 16; n=24, 39	-0.2 Millimoles per liter Standard Deviation 2.14	-0.3 Millimoles per liter Standard Deviation 2.01
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Sodium:Week 28; n=74, 73	0.5 Millimoles per liter Standard Deviation 2.55	-0.2 Millimoles per liter Standard Deviation 2.11
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Calcium: Week 2; n=72, 74	-0.006 Millimoles per liter Standard Deviation 0.0691	0.001 Millimoles per liter Standard Deviation 0.0925
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Calcium:Week 4; n=47,59	-0.013 Millimoles per liter Standard Deviation 0.0873	-0.005 Millimoles per liter Standard Deviation 0.0743
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Calcium:Week 8; n=34,47	-0.005 Millimoles per liter Standard Deviation 0.0648	-0.003 Millimoles per liter Standard Deviation 0.0997
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Calcium:Week 12; n=24, 36	0.018 Millimoles per liter Standard Deviation 0.0962	-0.004 Millimoles per liter Standard Deviation 0.0949
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Calcium:Week 16; n=24, 39	0.014 Millimoles per liter Standard Deviation 0.0950	0.017 Millimoles per liter Standard Deviation 0.0963
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Calcium:Week 28; n=74, 73	0.001 Millimoles per liter Standard Deviation 0.0776	0.001 Millimoles per liter Standard Deviation 0.0994
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Phosphate: Week 2; n=72, 74	0.031 Millimoles per liter Standard Deviation 0.1467	-0.023 Millimoles per liter Standard Deviation 0.1502
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Phosphate:Week 4; n=47,59	0.003 Millimoles per liter Standard Deviation 0.1312	-0.011 Millimoles per liter Standard Deviation 0.1362
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Phosphate:Week 8; n=34,47	0.006 Millimoles per liter Standard Deviation 0.1678	-0.049 Millimoles per liter Standard Deviation 0.1420
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Phosphate:Week 16; n=24, 39	-0.006 Millimoles per liter Standard Deviation 0.1370	-0.019 Millimoles per liter Standard Deviation 0.1503
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Chloride:Week 4; n=47,59	0.0 Millimoles per liter Standard Deviation 2.04	-0.3 Millimoles per liter Standard Deviation 2.18
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Chloride:Week 8; n=34,47	-0.2 Millimoles per liter Standard Deviation 1.97	0.0 Millimoles per liter Standard Deviation 2.03
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Chloride:Week 12; n=24, 36	-0.1 Millimoles per liter Standard Deviation 2.61	-0.3 Millimoles per liter Standard Deviation 2.13
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Chloride:Week 16; n=24, 39	-0.4 Millimoles per liter Standard Deviation 2.95	-0.2 Millimoles per liter Standard Deviation 2.61
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Chloride:Week 28; n=74, 73	0.6 Millimoles per liter Standard Deviation 2.65	0.7 Millimoles per liter Standard Deviation 2.24
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) CO2: Week 2; n=72, 74	-0.4 Millimoles per liter Standard Deviation 2.71	0.4 Millimoles per liter Standard Deviation 2.10
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) CO2:Week 4; n=47,59	-0.4 Millimoles per liter Standard Deviation 2.26	0.3 Millimoles per liter Standard Deviation 2.82
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) CO2:Week 8; n=34,46	-0.3 Millimoles per liter Standard Deviation 1.95	-0.3 Millimoles per liter Standard Deviation 1.84
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) CO2:Week 12; n=24, 36	-0.5 Millimoles per liter Standard Deviation 2.60	-0.1 Millimoles per liter Standard Deviation 2.10
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) CO2:Week 16; n=24, 39	-0.5 Millimoles per liter Standard Deviation 2.34	0.1 Millimoles per liter Standard Deviation 2.28
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) CO2:Week 28; n=74, 73	-0.1 Millimoles per liter Standard Deviation 2.28	0.3 Millimoles per liter Standard Deviation 2.15
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Urea: Week 2; n=72, 74	0.08 Millimoles per liter Standard Deviation 1.311	-0.14 Millimoles per liter Standard Deviation 1.108
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Urea:Week 4; n=47,59	0.16 Millimoles per liter Standard Deviation 1.344	-0.14 Millimoles per liter Standard Deviation 1.102
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Urea:Week 8; n=34,47	-0.04 Millimoles per liter Standard Deviation 1.264	0.27 Millimoles per liter Standard Deviation 1.151
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Urea:Week 12; n=24, 36	0.58 Millimoles per liter Standard Deviation 1.537	-0.06 Millimoles per liter Standard Deviation 1.346
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Urea:Week 16; n=24, 39	0.48 Millimoles per liter Standard Deviation 1.379	0.03 Millimoles per liter Standard Deviation 1.287
Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2) Urea:Week 28; n=74, 73	0.08 Millimoles per liter Standard Deviation 1.089	0.16 Millimoles per liter Standard Deviation 1.121

Measure	Placebo n=74 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Creatinine:Week 28; n=74, 73	4.32 Micromoles per liter Standard Deviation 6.810	2.9 Micromoles per liter Standard Deviation 6.356
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Creatinine: Week 2; n=72, 74	2.35 Micromoles per liter Standard Deviation 6.911	1.71 Micromoles per liter Standard Deviation 8.321
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Creatinine:Week 4; n=47, 59	2.35 Micromoles per liter Standard Deviation 8.319	0.72 Micromoles per liter Standard Deviation 6.610
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Creatinine:Week 8; n=34, 47	1.18 Micromoles per liter Standard Deviation 7.677	1.76 Micromoles per liter Standard Deviation 6.072
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Creatinine:Week 12; n=24, 36	2.42 Micromoles per liter Standard Deviation 6.521	0.02 Micromoles per liter Standard Deviation 5.866
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Creatinine:Week 16; n=24, 39	2.50 Micromoles per liter Standard Deviation 8.685	0.91 Micromoles per liter Standard Deviation 6.105
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Total Bilirubin : Week 2; n=72, 74	-0.1 Micromoles per liter Standard Deviation 3.22	0.1 Micromoles per liter Standard Deviation 2.83
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Total Bilirubin :Week 4; n=47, 59	-0.3 Micromoles per liter Standard Deviation 3.24	-0.4 Micromoles per liter Standard Deviation 2.98
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Total Bilirubin :Week 8; n=34, 47	-0.1 Micromoles per liter Standard Deviation 2.46	-0.2 Micromoles per liter Standard Deviation 4.04
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Total Bilirubin :Week 12; n=24, 36	-0.6 Micromoles per liter Standard Deviation 2.32	0.1 Micromoles per liter Standard Deviation 4.56
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Total Bilirubin :Week 16; n=24, 39	0.0 Micromoles per liter Standard Deviation 2.83	-0.3 Micromoles per liter Standard Deviation 3.39
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Total Bilirubin :Week 28; n=74, 74	0.1 Micromoles per liter Standard Deviation 2.77	-0.5 Micromoles per liter Standard Deviation 3.94
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Direct bilirubin : Week 2; n=72, 74	-0.1 Micromoles per liter Standard Deviation 1.18	0.0 Micromoles per liter Standard Deviation 1.02
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Direct bilirubin :Week 4; n=47,59	-0.1 Micromoles per liter Standard Deviation 0.97	0.1 Micromoles per liter Standard Deviation 1.11
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Direct bilirubin :Week 8; n=34, 47	-0.1 Micromoles per liter Standard Deviation 1.04	0.2 Micromoles per liter Standard Deviation 1.17
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Direct bilirubin :Week 12; n=24, 36	-0.4 Micromoles per liter Standard Deviation 1.18	0.2 Micromoles per liter Standard Deviation 1.11
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Direct bilirubin :Week 16; n=24, 39	0.1 Micromoles per liter Standard Deviation 1.50	0.1 Micromoles per liter Standard Deviation 1.07
Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin Direct bilirubin :Week 28; n=74, 74	0.1 Micromoles per liter Standard Deviation 1.17	0.1 Micromoles per liter Standard Deviation 1.13

Measure	Placebo n=78 Participants Participants were administered placebo via intravenous (IV) route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of fluticasone propionate/ salmeterol (FP/Sal) 500/50 micrograms (mcg) twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the End of Treatment Period (ETP) Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.	GSK3772847 n=74 Participants Participants were administered 10 milligram/kilogram (mg/kg) GSK3772847 via IV route every 4 weeks (Weeks 0, 4, 8 and 12) in addition to open-label background therapy of FP/Sal 500/50 mcg twice daily. After 2 weeks, the background therapy was switched to FP 500 mcg for 2 weeks and the dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation. Three Follow-up visits were performed after the ETP Visit (Weeks 20, 24, and 28) for safety assessments. Participants received salbutamol/albuterol to use as needed for asthma symptom relief.
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 16; n=23, 39	-0.41 10^9 cells per liter Standard Deviation 1.296	0.18 10^9 cells per liter Standard Deviation 1.511
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 28; n=65, 60	0.041 10^9 cells per liter Standard Deviation 0.1431	0.066 10^9 cells per liter Standard Deviation 0.1218
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 12; n=24, 39	3.6 10^9 cells per liter Standard Deviation 46.24	6.6 10^9 cells per liter Standard Deviation 27.79
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 14; n=24, 39	-6.4 10^9 cells per liter Standard Deviation 45.37	5.5 10^9 cells per liter Standard Deviation 32.66
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 16; n=24, 38	-0.5 10^9 cells per liter Standard Deviation 37.57	6.3 10^9 cells per liter Standard Deviation 40.13
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 28; n=64, 62	-3.5 10^9 cells per liter Standard Deviation 35.52	3.0 10^9 cells per liter Standard Deviation 52.16
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 28; n= 65, 60	0.006 10^9 cells per liter Standard Deviation 0.0364	0.007 10^9 cells per liter Standard Deviation 0.0353
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil: Week 1; n=77, 74	-0.031 10^9 cells per liter Standard Deviation 0.2868	-0.038 10^9 cells per liter Standard Deviation 0.1424
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil: Week 1; n=77, 74	0.001 10^9 cells per liter Standard Deviation 0.0361	-0.001 10^9 cells per liter Standard Deviation 0.0396
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 2; n= 68, 72	0.003 10^9 cells per liter Standard Deviation 0.0350	0.005 10^9 cells per liter Standard Deviation 0.0346
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 4; n=48, 57	0.005 10^9 cells per liter Standard Deviation 0.0341	0.004 10^9 cells per liter Standard Deviation 0.0409
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 6; n=43, 54	0.006 10^9 cells per liter Standard Deviation 0.0420	0.007 10^9 cells per liter Standard Deviation 0.0363
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 8; n=33, 46	0.002 10^9 cells per liter Standard Deviation 0.0449	-0.001 10^9 cells per liter Standard Deviation 0.0366
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 10; n= 32, 44	0.004 10^9 cells per liter Standard Deviation 0.0345	0.010 10^9 cells per liter Standard Deviation 0.0367
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 12; n=24, 39	0.010 10^9 cells per liter Standard Deviation 0.0262	0.010 10^9 cells per liter Standard Deviation 0.0312
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 14; n=23, 39	-0.003 10^9 cells per liter Standard Deviation 0.0255	0.012 10^9 cells per liter Standard Deviation 0.0338
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Basophil:Week 16; n=23, 39	-0.005 10^9 cells per liter Standard Deviation 0.0316	0.006 10^9 cells per liter Standard Deviation 0.0409
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 2; n=68, 72	-0.050 10^9 cells per liter Standard Deviation 0.2105	-0.051 10^9 cells per liter Standard Deviation 0.1892
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 4; n=48, 57	-0.048 10^9 cells per liter Standard Deviation 0.2585	-0.119 10^9 cells per liter Standard Deviation 0.1522
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 6; n =43, 54	-0.023 10^9 cells per liter Standard Deviation 0.2714	-0.119 10^9 cells per liter Standard Deviation 0.1950
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 8; n= 33, 46	-0.014 10^9 cells per liter Standard Deviation 0.2069	-0.096 10^9 cells per liter Standard Deviation 0.2134
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 10 n=32, 44	0.000 10^9 cells per liter Standard Deviation 0.2387	-0.041 10^9 cells per liter Standard Deviation 0.2371
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 12; n=24, 39	-0.039 10^9 cells per liter Standard Deviation 0.2621	-0.066 10^9 cells per liter Standard Deviation 0.1939
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 14; n=23, 39	0.018 10^9 cells per liter Standard Deviation 0.1888	-0.034 10^9 cells per liter Standard Deviation 0.2481
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 16; n=23, 39	-0.018 10^9 cells per liter Standard Deviation 0.2456	-0.093 10^9 cells per liter Standard Deviation 0.2350
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Eosinophil:Week 28; n= 65, 60	0.010 10^9 cells per liter Standard Deviation 0.2077	-0.087 10^9 cells per liter Standard Deviation 0.1865
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes: Week 1; n=78, 74	0.14 10^9 cells per liter Standard Deviation 1.614	0.07 10^9 cells per liter Standard Deviation 1.314
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 2; n= 68, 73	0.01 10^9 cells per liter Standard Deviation 1.202	0.09 10^9 cells per liter Standard Deviation 1.117
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 4; n =48, 57	0.24 10^9 cells per liter Standard Deviation 1.406	0.19 10^9 cells per liter Standard Deviation 1.401
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 6; n=43, 54	0.37 10^9 cells per liter Standard Deviation 1.346	-0.12 10^9 cells per liter Standard Deviation 1.040
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 8; n=33, 47	0.08 10^9 cells per liter Standard Deviation 1.045	0.14 10^9 cells per liter Standard Deviation 2.248
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 10; n=33, 45	0.01 10^9 cells per liter Standard Deviation 1.102	0.03 10^9 cells per liter Standard Deviation 1.259
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 12; n=24, 39	0.13 10^9 cells per liter Standard Deviation 1.257	0.18 10^9 cells per liter Standard Deviation 1.038
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 14; n= 23, 39	-0.17 10^9 cells per liter Standard Deviation 1.324	0.26 10^9 cells per liter Standard Deviation 1.220
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Leukocytes:Week 28; n=65, 63	-0.08 10^9 cells per liter Standard Deviation 1.545	0.09 10^9 cells per liter Standard Deviation 1.392
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes: Week 1; n=77, 74	0.036 10^9 cells per liter Standard Deviation 0.4248	-0.008 10^9 cells per liter Standard Deviation 0.3292
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 2; n=68, 72	0.006 10^9 cells per liter Standard Deviation 0.3437	0.039 10^9 cells per liter Standard Deviation 0.4112
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 4; n=48, 57	0.043 10^9 cells per liter Standard Deviation 0.4048	0.061 10^9 cells per liter Standard Deviation 0.2995
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 6; n=43, 54	0.140 10^9 cells per liter Standard Deviation 0.4994	0.086 10^9 cells per liter Standard Deviation 0.3986
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 8; n=33, 46	0.132 10^9 cells per liter Standard Deviation 0.3257	0.033 10^9 cells per liter Standard Deviation 0.3477
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 10; n=32, 44	0.103 10^9 cells per liter Standard Deviation 0.4275	0.105 10^9 cells per liter Standard Deviation 0.4105
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 12; n=24, 39	0.098 10^9 cells per liter Standard Deviation 0.3657	0.044 10^9 cells per liter Standard Deviation 0.3546
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 14; n=23, 39	0.009 10^9 cells per liter Standard Deviation 0.3590	0.119 10^9 cells per liter Standard Deviation 0.4346
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 16; n=23, 39	0.02 10^9 cells per liter Standard Deviation 0.3825	0.075 10^9 cells per liter Standard Deviation 0.4397
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Lymphocytes:Week 28; n=65, 60	0.065 10^9 cells per liter Standard Deviation 0.4601	0.162 10^9 cells per liter Standard Deviation 0.4794
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils: Week 1; n=77, 74	0.079 10^9 cells per liter Standard Deviation 1.4665	0.092 10^9 cells per liter Standard Deviation 1.1019
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 2; n=68, 72	0.023 10^9 cells per liter Standard Deviation 1.0414	0.035 10^9 cells per liter Standard Deviation 0.8299
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 4; n=48, 57	0.187 10^9 cells per liter Standard Deviation 1.2738	0.217 10^9 cells per liter Standard Deviation 1.2788
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 6; n=43, 54	0.203 10^9 cells per liter Standard Deviation 1.3952	-0.126 10^9 cells per liter Standard Deviation 0.8524
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 8; n=33, 46	-0.080 10^9 cells per liter Standard Deviation 0.9654	0.331 10^9 cells per liter Standard Deviation 2.0776
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 10; n=32, 44	-0.192 10^9 cells per liter Standard Deviation 0.9739	0.041 10^9 cells per liter Standard Deviation 0.9173
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 12; n=24, 39	-0.013 10^9 cells per liter Standard Deviation 1.2306	0.158 10^9 cells per liter Standard Deviation 0.8630
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 14; n=23, 39	-0.263 10^9 cells per liter Standard Deviation 1.3117	0.073 10^9 cells per liter Standard Deviation 0.9305
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 16; n=23, 39	-0.448 10^9 cells per liter Standard Deviation 1.1201	0.142 10^9 cells per liter Standard Deviation 1.2595
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Neutrophils:Week 28; n=65, 60	-0.201 10^9 cells per liter Standard Deviation 1.5148	-0.045 10^9 cells per liter Standard Deviation 1.1145
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes: Week 1; n=77, 74	0.026 10^9 cells per liter Standard Deviation 0.1595	0.015 10^9 cells per liter Standard Deviation 0.1209
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 2; n=68, 72	0.020 10^9 cells per liter Standard Deviation 0.1226	0.022 10^9 cells per liter Standard Deviation 0.0965
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 4; n=48, 57	0.051 10^9 cells per liter Standard Deviation 0.1869	0.027 10^9 cells per liter Standard Deviation 0.1014
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 6; n=43, 54	0.050 10^9 cells per liter Standard Deviation 0.1353	0.038 10^9 cells per liter Standard Deviation 0.1083
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 8; n=33, 46	0.045 10^9 cells per liter Standard Deviation 0.1152	0.023 10^9 cells per liter Standard Deviation 0.1038
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 10; n=32, 44	0.090 10^9 cells per liter Standard Deviation 0.1463	0.038 10^9 cells per liter Standard Deviation 0.100
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 12; n=24, 39	0.073 10^9 cells per liter Standard Deviation 0.1362	0.025 10^9 cells per liter Standard Deviation 0.0948
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 14; n=23, 39	0.059 10^9 cells per liter Standard Deviation 0.1301	0.082 10^9 cells per liter Standard Deviation 0.103
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Monocytes:Week 16; n=23, 39	0.040 10^9 cells per liter Standard Deviation 0.1087	0.053 10^9 cells per liter Standard Deviation 0.1075
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets: Week 1; n=78, 74	1.5 10^9 cells per liter Standard Deviation 31.89	8.7 10^9 cells per liter Standard Deviation 44.52
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 2; n=71, 74	7.6 10^9 cells per liter Standard Deviation 35.72	9.8 10^9 cells per liter Standard Deviation 44.42
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 4; n=49, 57	4.0 10^9 cells per liter Standard Deviation 27.64	5.3 10^9 cells per liter Standard Deviation 33.05
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 6; n=44, 56	18.2 10^9 cells per liter Standard Deviation 46.02	3.9 10^9 cells per liter Standard Deviation 35.62
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 8; n=34, 47	8.6 10^9 cells per liter Standard Deviation 38.79	-1.1 10^9 cells per liter Standard Deviation 30.31
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets Platelets:Week 10; n=34, 45	10.9 10^9 cells per liter Standard Deviation 45.93	4.7 10^9 cells per liter Standard Deviation 30.88